<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rituximab (intravenous) including biosimilars: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rituximab (intravenous) including biosimilars: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Rituximab (intravenous) including biosimilars: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9616" href="/d/html/9616.html" rel="external">see "Rituximab (intravenous) including biosimilars: Drug information"</a> and <a class="drug drug_patient" data-topicid="11030" href="/d/html/11030.html" rel="external">see "Rituximab (intravenous) including biosimilars: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709404"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Infusion-related reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Rituximab administration can result in serious, including fatal, infusion-related reactions. Deaths within 24 hours of rituximab infusion have occurred. Approximately 80% of fatal infusion-related reactions occurred in association with the first infusion. Monitor patients closely. Discontinue rituximab infusion for severe reactions and provide medical treatment for grade 3 or 4 infusion-related reactions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mucocutaneous reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab products.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatitis B virus reactivation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hepatitis B virus (HBV) reactivation can occur in patients treated with rituximab products, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with rituximab. Discontinue rituximab and concomitant medications in the event of HBV reactivation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Progressive multifocal leukoencephalopathy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Progressive multifocal leukoencephalopathy (PML), including fatal PML, can occur in patients receiving rituximab products.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F218842"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Riabni;</li>
<li>Rituxan;</li>
<li>Ruxience;</li>
<li>Truxima</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868174"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Riabni;</li>
<li>Rituxan;</li>
<li>Riximyo;</li>
<li>Ruxience;</li>
<li>Truxima</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1049762"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Anti-CD20</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Monoclonal Antibody</span>;</li>
<li>
<span class="list-set-name">Antirheumatic Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Immunosuppressant Agent</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F2197623"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Safety:</b> Prior to rituximab therapy, patients should be brought up to date with all nonlive vaccination if possible; any nonlive vaccines should be administered ≥4 weeks prior to first rituximab dose. Pretreatment with acetaminophen and an antihistamine (diphenhydramine typically used in pediatric trials) is recommended for all indications.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>In the United States, Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), and Truxima (rituximab-abbs) are approved biosimilars to Rituxan (rituximab). In Canada, Riximyo, Ruxience, and Truxima are approved biosimilars to Rituxan (rituximab); refer to Canadian product monographs for biosimilar-specific labeled indications. Approved ages and uses may vary (consult product labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> For oncology uses, a uricostatic agent (eg, allopurinol) and aggressive hydration are recommended for patients at risk for tumor lysis syndrome (high tumor burden or lymphocytes &gt;25,000/mm<sup>3</sup>) and dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7a6efa5e-d33c-41a0-9fd7-7cfa2dcc9d7b">Acute lymphoblastic leukemia, mature B-cell, CD 20+; relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, mature B-cell, CD 20+ (B-ALL); relapsed/refractory:</b> Limited data available: Children ≥5 years and Adolescents: IV infusion: 375 mg/m<sup>2</sup> administered on days 1 and 3 of courses 1 and 2 and on day 1 only of course 3; used in combination with ifosfamide, carboplatin, and etoposide (ICE) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18816698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18816698'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc703a95-c746-4659-bc8f-b2eeb6c8ed9a">Autoimmune hemolytic anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Autoimmune hemolytic anemia:</b> Limited data available: Infants ≥4 months, Children, and Adolescents: IV infusion: 375 mg/m<sup>2</sup> once weekly for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28444729','lexi-content-ref-28151390','lexi-content-ref-25139610','lexi-content-ref-12531800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28444729','lexi-content-ref-28151390','lexi-content-ref-25139610','lexi-content-ref-12531800'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="057098ed-7246-40d6-be60-464f4f65eb7d">Graft-versus-host disease, chronic, steroid refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, chronic (cGVHD), steroid refractory:</b> Limited data available: Children and Adolescents: IV: 375 mg/m<sup>2</sup> once weekly for 4 doses followed by monthly infusions has been reported; in preliminary data, GVHD musculoskeletal and dermal manifestations were observed to respond better than ophthalmic, hepatic, or gastrointestinal manifestations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20663943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20663943'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="185a1c3f-80a5-43b0-bc65-d3f713841c24">Granulomatosis with polyangiitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Granulomatosis with polyangiitis (GPA, Wegener granulomatosis): Note:</b> In addition to an antihistamine and acetaminophen, patients should also be premedicated 30 minutes prior to each infusion with methylprednisolone (eg, 100 mg IV in adults or equivalent). Patients should receive <i>Pneumocystis jirovecii</i> pneumonia (PCP) prophylaxis during rituximab therapy and for at least 6 months following the last rituximab dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction (active GPA): IV: 375 mg/m<sup>2</sup> once weekly for 4 doses.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Use rituximab in combination with corticosteroids (ie, methylprednisolone or oral corticosteroid taper). Prior to the first dose of rituximab, methylprednisolone should be administered for 3 days (30 mg/kg/dose once daily; maximum dose: 1,000 mg/dose) followed by oral corticosteroid taper per usual clinical practice and patient response.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance (once disease control achieved): IV: 250 mg/m<sup>2</sup> every 2 weeks for 2 doses, followed by 250 mg/m<sup>2</sup> every 6 months based upon clinical response. Begin maintenance regimen within 16 to 24 weeks of last rituximab induction dose. If rituximab was not part of induction regimen, begin rituximab within 4 weeks of achieving disease control.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf8c5fcc-fb14-45eb-8805-d6eed35c08c4">Immune thrombocytopenic purpura, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenic purpura, chronic:</b> Limited data available: Children and Adolescents: IV infusion: 375 mg/m<sup>2</sup> once weekly for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16352811','lexi-content-ref-19036077','lexi-content-ref-16933264','lexi-content-ref-15689912']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16352811','lexi-content-ref-19036077','lexi-content-ref-16933264','lexi-content-ref-15689912'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3df79085-820c-4e7a-9789-a17007ed5527">Leukemia, acute B-cell; CD20+; advanced stage, previously untreated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukemia, acute B-cell; CD20+; advanced stage, previously untreated:</b> Infants ≥6 months, Children, and Adolescents: IV infusion: 375 mg/m<sup>2</sup>/dose in combination with systemic Lymphome Malin B (LMB) chemotherapy regimen; administer 2 doses during each induction course (day −2 and day 1), and 1 dose on day 1 of each of the 2 consolidation cycles (6 doses total).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a5f173ca-fba6-4d74-9b05-50ff4cb6356a">Microscopic polyangiitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Microscopic polyangiitis (MPA): Note:</b> In addition to an antihistamine and acetaminophen, patients should also be premedicated 30 minutes prior to each infusion with methylprednisolone (eg, 100 mg IV in adults or equivalent). Patients should receive PCP prophylaxis during rituximab therapy and for at least 6 months following the last rituximab dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction (active MPA): IV: 375 mg/m<sup>2</sup> once weekly for 4 doses.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Use rituximab in combination with corticosteroids (ie, methylprednisolone or oral corticosteroid taper). Prior to the first dose of rituximab, methylprednisolone should be administered for 3 days (30 mg/kg/dose once daily; maximum dose: 1,000 mg/dose) followed by oral corticosteroid taper per usual clinical practice and patient response.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance (once disease control achieved): IV: 250 mg/m<sup>2</sup> every 2 weeks for 2 doses, followed by 250 mg/m<sup>2</sup> every 6 months based upon clinical response. Begin maintenance regimen within 16 to 24 weeks of last rituximab induction dose. If rituximab was not part of induction regimen, begin rituximab within 4 weeks of achieving disease control.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="012d18cc-04c5-4a00-ab02-23aa37598de2">Nephrotic syndrome, steroid-dependent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrotic syndrome, steroid-dependent:</b> Limited data available; use should be reserved for patients with frequent relapses despite optimal combinations of prednisone and corticosteroid-sparing therapy or intolerance to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>). Children and Adolescents: IV infusion: 375 mg/m<sup>2</sup> once weekly for 1 to 4 doses; a maximum dose of 500 mg/dose has been reported in some, but not all, reports; dosing based on small trials, case series, and retrospective analyses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18465150','lexi-content-ref-20798255','lexi-content-ref-24965823','lexi-content-ref-19421786','lexi-content-ref-20033225','lexi-content-ref-27409338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18465150','lexi-content-ref-20798255','lexi-content-ref-24965823','lexi-content-ref-19421786','lexi-content-ref-20033225','lexi-content-ref-27409338'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b2e2023-812b-49ee-8d04-c65da08a43d8">Non-Hodgkin lymphoma B-cell, CD 20+; relapsed and refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma B-cell, CD 20+; relapsed and refractory:</b> Limited data available: Children ≥11 years and Adolescents: IV infusion: 375 mg/m<sup>2</sup> administered on days 1 and 3 of courses 1 and 2 and on day 1 only of course 3; used in combination with ICE (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18816698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18816698'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9ef677cb-e57c-4417-a8d3-52510c21ad93">Non-Hodgkin lymphoma; CD20+, diffuse large B-cell, Burkitt lymphoma, Burkitt-like lymphoma; previously untreated, advanced stage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non</b>
<b>-Hodgkin lymphoma; CD20+, diffuse large B-cell (DLBCL), Burkitt lymphoma, Burkitt-like lymphoma; previously untreated, advanced stage:</b> Infants ≥6 months, Children, and Adolescents: IV infusion: 375 mg/m<sup>2</sup>/dose in combination with systemic Lymphome Malin B (LMB) chemotherapy regimen; administer 2 doses during each induction course (day −2 and day 1), and 1 dose on day 1 of each of the 2 consolidation cycles (6 doses total).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2db699d8-b484-4743-9770-57a0112e43f4">Posttransplant lymphoproliferative disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttransplant lymphoproliferative disorder:</b> Limited data available: Infants ≥11 months, Children, and Adolescents: IV infusion: 375 mg/m<sup>2</sup> once weekly for 3 to 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10707791','lexi-content-ref-11930095']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10707791','lexi-content-ref-11930095'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="110292f2-f0f7-4f0b-88d5-496c57489915">Primary mediastinal large B-cell lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary mediastinal large B-cell lymphoma:</b> Limited data available: Children and Adolescents: IV: 375 mg/m<sup>2</sup> every 21 to 28 days for 6 to 8 doses; use in combination with multi-agent chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17233819','lexi-content-ref-29082519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17233819','lexi-content-ref-29082519'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9922c6d4-eec2-45bf-8da9-7dda1e71cf5f">Systemic lupus erythematosus; refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic lupus erythematosus; refractory:</b> Limited data available; various dosing regimens reported in small open-labeled trials and case series; experts suggest rituximab as an option in nonresponders if more than one initial therapy has failed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>): Children ≥6 years and Adolescents: IV infusion: Usual regimen: Initial dose: 187.5 mg/m<sup>2 </sup>once (day 1) followed by 375 mg/m<sup>2</sup> once weekly for 1 to 3 doses (days 8, 15, 22) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18097688','lexi-content-ref-21799148']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18097688','lexi-content-ref-21799148'])">Ref</a></span>); other reports omit the lower initial dose and administer 375 mg/m<sup>2</sup> once weekly beginning on day 1 for 2 to 4 doses (days 8, 15, 22) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16737873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16737873'])">Ref</a></span>). Others have reported a higher dose regimen of 750 mg/m<sup>2</sup> on days 1 and 15 (maximum dose: 1,000 mg/dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16200620','lexi-content-ref-18039744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16200620','lexi-content-ref-18039744'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192773"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51192774"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F218845"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9616" href="/d/html/9616.html" rel="external">see "Rituximab (intravenous) including biosimilars: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Administer appropriate immunizations prior (eg, ≥4 weeks) to starting therapy (if possible) and screen for active or latent infections. Avoid use in patients with severe active infection. Prophylaxis against opportunistic infection and/or viral reactivation may be warranted during and up to 12 months after completion of rituximab therapy. Manufacturer's labeling recommends premedicating ~30 minutes prior to administration with acetaminophen, an antihistamine, and methylprednisolone 100 mg IV (or equivalent). For uses requiring concomitant administration with a glucocorticoid (eg, some oncology uses), administer glucocorticoid component of the chemotherapy regimen prior to rituximab infusion. Premedication practice may vary; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>In the United States, Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), and Truxima (rituximab-abbs) are approved biosimilars to Rituxan (rituximab). In Canada, Riximyo, Ruxience, and Truxima are approved biosimilars to Rituxan (rituximab); refer to Canadian product monographs for biosimilar-specific labeled indications.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7bd05b7-57cc-4ccf-a253-bee25c9cde6c">Acute lymphoblastic leukemia, B-cell precursor, CD20-positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, B-cell precursor, CD20-positive (off-label use): Note:</b> Antihyperuricemic therapy and aggressive hydration are recommended for patients at high risk for tumor lysis syndrome (high tumor burden or lymphocytes ≥25,000/mm<sup>3</sup>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GRAALL 2005-R:</i> Adults &lt;60 years of age: <b>IV: </b>375 mg/m<sup>2</sup> on days 1 and 7 of induction (and days 1 and 7 of salvage cycle, if needed), on days 1 and 29 of consolidation 1 and 2, on days 1 and 7 of late intensification, on days 1 and 29 of consolidation 3, and on day 1 of reinductions 1, 3, 5, 7, 9, and 11 of the maintenance phase for a total of 16 to 18 rituximab doses. <b>Note: </b>Administer rituximab after hydration and before chemotherapy; administer rituximab after steroids, if both are administered on the same day. If the initial WBC is &gt;30,000/mm<sup>3</sup> on day 1 after the steroid prophase, split rituximab administration into 100 mg/m<sup>2</sup> on days 1 and 2, followed by 175 mg/m<sup>2</sup> on day 3 (total dose: 375 mg/m<sup>2</sup>). Refer to protocol for further information regarding concomitant chemotherapy agents, dosing, and administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27626518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27626518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rituximab in combination with hyper-CVAD: </i>Adults &lt;60 years of age: <b>IV: </b>375 mg/m<sup>2</sup> on days 1 and 11 of hyper-CVAD cycles (cyclophosphamide, mesna, dexamethasone, doxorubicin, and vincristine) and on days 1 and 8 of high-dose methotrexate and cytarabine cycles, for a total of 8 rituximab doses over the first 4 courses; rituximab was also administered with early and late hyper-CVAD intensifications during months 6 and 18 of maintenance therapy (on days 1 and 11). Refer to protocol for further information regarding concomitant chemotherapy agents, dosing, and administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20660823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20660823'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7073a9e6-1a73-4b88-8882-0c814488709d">Antibody-mediated rejection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antibody-mediated rejection, treatment (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen. If plasmapheresis is utilized, administer after completion of plasmapheresis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23432476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23432476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heart</i>
<i> transplantation (off-label use):</i>
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly for 1 to 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25838326','lexi-content-ref-37080658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25838326','lexi-content-ref-37080658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i></i>
<i>Kidney transplantation (off-label use): </i>
<b>Note:</b> For use in patients with evidence of microvascular inflammation on biopsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Djamali.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Djamali.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly for 1 to 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17496547','lexi-content-ref-19200217','lexi-content-ref-19422335','lexi-content-ref-29536028']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17496547','lexi-content-ref-19200217','lexi-content-ref-19422335','lexi-content-ref-29536028'])">Ref</a></span>). Some experts administer a single dose of 200 to 375 mg/m<sup>2 </sup>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Djamali.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Djamali.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Liver transplantation, treatment refractory (off-label use)</i>
<b>: IV: </b>375 mg/m<sup>2</sup> once weekly for 1 to 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34480762','lexi-content-ref-19610146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34480762','lexi-content-ref-19610146'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lung transplantation (off-label use):</i>
<b>IV:</b> 375 mg/m<sup>2</sup> once; may administer a second dose of 375 mg/m<sup>2</sup> after ~2 weeks if donor-specific antibodies are still present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20558084','lexi-content-ref-Hachem.1','lexi-content-ref-27988971','lexi-content-ref-23953920','lexi-content-ref-31435872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20558084','lexi-content-ref-Hachem.1','lexi-content-ref-27988971','lexi-content-ref-23953920','lexi-content-ref-31435872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i></i>
<i>Pancreas transplantation (off-label use):</i>
<b>IV:</b> 375 mg/m<sup>2</sup> administered in 2-week intervals for a total of 1 to 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Alhamad.1','lexi-content-ref-16426331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Alhamad.1','lexi-content-ref-16426331'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e4c63d40-64d3-4f01-a42f-f6676147d622">Burkitt lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Burkitt lymphoma (off-label use): Note:</b> Antihyperuricemic therapy and aggressive hydration are recommended for patients at high risk for tumor lysis syndrome (high tumor burden or lymphocytes ≥25,000/mm<sup>3</sup>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 375 mg/m<sup>2</sup> on days 1 and 11 of cycles 1 and 3 and days 2 and 8 of cycles 2 and 4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16502413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16502413'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> at the start of each chemotherapy cycle, followed by 2 additional doses 3 and 6 weeks after the completion of chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25359988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25359988'])">Ref</a></span>) <b>or</b> 50 mg/m<sup>2</sup> on day 8 and 375 mg/m<sup>2</sup> on days 10 and 12 of cycle 2 followed by 375 mg/m<sup>2</sup> on day 8 of cycles 3 to 7 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24428673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24428673'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c2daff1-da41-460d-97f5-616d486189ba">Chronic lymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia: Note:</b> Antihyperuricemic therapy and aggressive hydration are recommended for patients at high risk for tumor lysis syndrome (high tumor burden or lymphocytes ≥25,000/mm<sup>3</sup>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rituxan and rituximab biosimilars:</b>
<b>IV:</b> 375 mg/m<sup>2</sup> on the day prior to fludarabine/cyclophosphamide in cycle 1, then 500 mg/m<sup>2</sup> on day 1 (every 28 days) of cycles 2 to 6 (in combination with fludarabine and cyclophosphamide).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Off-label chronic lymphocytic leukemia combinations:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Previously untreated chronic lymphocytic leukemia (CLL): </i>
<b>IV: </b>375 mg/m<sup>2</sup> on the day prior to bendamustine in cycle 1, then 500 mg/m<sup>2</sup> on day 1 (every 28 days) of cycles 2 to 6 (in combination with bendamustine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27216274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27216274'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> on days 1 and 4 of cycle 1 (or 50 mg/m<sup>2</sup> on day 1, followed by 325 mg/m<sup>2</sup> on day 3, followed by 375 mg/m<sup>2</sup> on day 5 of cycle 1), then 375 mg/m<sup>2</sup> on day 1 (every 28 days) of cycles 2 to 6 (in combination with fludarabine; refer to protocol for rituximab dosing and infusion parameters) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12393429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12393429'])">Ref</a></span>) <b>or</b> 50 mg/m<sup>2</sup> on day 1 of cycle 2, followed by 325 mg/m<sup>2</sup> on day 2 of cycle 2, followed by 500 mg/m<sup>2</sup> on day 1 of cycles 3 to 7 (in combination with ibrutinib in patients &lt;70 years of age with IGHV-unmutated CLL without 17p deletion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31365801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31365801'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Relapsed or refractory chronic lymphocytic leukemia:</i>
<b>IV: </b>375 mg/m<sup>2</sup> on day 1, followed by 500 mg/m<sup>2</sup> every 14 days for 4 doses and then 500 mg/m<sup>2</sup> every 28 days for 3 doses (in combination with idelalisib) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24450857','lexi-content-ref-30995176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24450857','lexi-content-ref-30995176'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> on the day prior to bendamustine in cycle 1, then 500 mg/m<sup>2</sup> on day 1 (every 28 days) of cycles 2 to 6 (in combination with bendamustine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21844497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21844497'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> on day 1 of cycle 1, then 500 mg/m<sup>2</sup> on day 1 (every 28 days) of cycles 2 to 6 (in combination with bendamustine and ibrutinib) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26655421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26655421'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> on day 1 of cycle 1 (following completion of dose ramp-up for venetoclax), then 500 mg/m<sup>2</sup> on day 1 (every 28 days) of cycles 2 to 6 (in combination with venetoclax) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30523712','lexi-content-ref-32986498','lexi-content-ref-29562156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30523712','lexi-content-ref-32986498','lexi-content-ref-29562156'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1b9f6ba-4e9c-4887-bc39-0a4bbe29e818">Dermatomyositis/Polymyositis, refractory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatomyositis and polymyositis, refractory</b>
<b> disease (alternative agent) (off-label use):</b>
<b></b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Note: </b>For use in patients who do not respond sufficiently to conventional induction regimens (eg, systemic glucocorticoids plus azathioprine or methotrexate). Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 g once every 2 weeks for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21571768','lexi-content-ref-16541475','lexi-content-ref-23124935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21571768','lexi-content-ref-16541475','lexi-content-ref-23124935'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18e6e26c-d8fa-42b9-8a6b-e440bcbad715">Eosinophilic granulomatosis with polyangiitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients with severe disease (in combination with glucocorticoids) to initiate disease remission or to re-induce remission following relapse. May also be considered as alternative maintenance therapy in patients with severe disease (if remission was induced with rituximab) or in those who are unable to receive first-line therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235894']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235894'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>375 mg/m<sup>2</sup> once weekly for 4 doses <b>or</b> 1 g once every 2 weeks for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33001543','lexi-content-ref-34235894','lexi-content-ref-31245051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33001543','lexi-content-ref-34235894','lexi-content-ref-31245051'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="057098ed-7246-40d6-be60-464f4f65eb7d">Graft-versus-host disease, chronic, steroid refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, chronic, steroid refractory (off-label use):</b>
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly for 4 doses; a second course of 4 weekly doses may be administered 8 weeks after initial therapy for lack of or incomplete response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16551963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16551963'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> once weekly for 4 to 8 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20685255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20685255'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2add0878-e7f8-494c-97bc-613da8b4bae5">Granulomatosis with polyangiitis or microscopic polyangiitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Granulomatosis with polyangiitis or microscopic polyangiitis (Rituxan and rituximab biosimilars): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on disease severity, organ system(s) involved, and institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Induction therapy: </i>
<b></b>
<b>Note:</b> For use in patients with active, severe disease; may also be used to re-induce remission in patients with severe disease relapse or in patients with refractory disease. In patients with nonsevere disease, rituximab may be used as alternative induction therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235894']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235894'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>375 mg/m<sup>2</sup> once weekly for 4 doses (manufacturer’s labeling) <b>or</b> 1 g once every 2 weeks for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235894','lexi-content-ref-22729997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235894','lexi-content-ref-22729997'])">Ref</a></span>); for either dosing regimen, administer in combination with a systemic glucocorticoid.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i></i>
<i>Maintenance therapy (after achieving disease control with induction): </i>
<b>Note:</b> For use in patients with severe disease, or as alternative to first-line agents in patients with nonsevere disease if remission was induced with rituximab or cyclophosphamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235894']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235894'])">Ref</a></span>). If induction for active disease was with rituximab, begin rituximab maintenance therapy within 4 to 6 months of the last rituximab induction dose. If induction therapy was cyclophosphamide-based, begin rituximab maintenance therapy within 1 month following WBC recovery. Duration varies according to risk of relapse and may range from 6 months to indefinite use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29695500','lexi-content-ref-25372085','lexi-content-ref-24626432','lexi-content-ref-22729997','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29695500','lexi-content-ref-25372085','lexi-content-ref-24626432','lexi-content-ref-22729997','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b></b>
<b>IV:</b> 500 mg once every 2 weeks for 2 doses, then 500 mg or 1 g once every 4 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29695500','lexi-content-ref-25372085','lexi-content-ref-24626432','lexi-content-ref-22729997','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29695500','lexi-content-ref-25372085','lexi-content-ref-24626432','lexi-content-ref-22729997','lexi-content-ref-Manu.1'])">Ref</a></span>). Alternatively, some experts prefer to omit 500 mg once every 2 weeks for 2 doses and proceed with 500 mg or 1 g once every 4 to 6 months; other experts only re-dose intermittently with 500 mg or 1 g when peripheral CD19+ lymphocyte count reconstitutes and ANCA titers become positive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Merkel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Merkel.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6809a202-6933-4fe2-a689-981abd6e2a63">Hairy cell leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hairy cell leukemia (off-label use): Note:</b> Antihyperuricemic therapy and aggressive hydration are recommended for patients at high risk for tumor lysis syndrome (high tumor burden or lymphocytes ≥25,000/mm<sup>3</sup>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with cladribine (as initial treatment or after first relapse): </i>
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly (beginning 28 days ± 4 days after initiation of 5 days of cladribine) for 8 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27301277','lexi-content-ref-21821712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27301277','lexi-content-ref-21821712'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> once weekly (beginning concurrently with cladribine) for 8 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109194'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with vemurafenib (relapsed or refractory disease): </i>
<b>IV:</b> 375 mg/m<sup>2</sup> on days 1 and 15 every 6 weeks (in combination with vemurafenib) for 2 induction cycles, followed by 375 mg/m<sup>2</sup> once every 2 weeks for 4 rituximab monotherapy consolidation doses (total of 8 rituximab doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33979489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33979489'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9aea909a-a37a-459a-bbda-5dae0f6e9f33">Hodgkin lymphoma, nodular lymphocyte-predominate, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, nodular lymphocyte-predominate, advanced (off-label use): </b>
<b>Note: </b>Antihyperuricemic therapy and aggressive hydration are recommended for patients at high risk for tumor lysis syndrome (high tumor burden or lymphocytes ≥25,000/mm<sup>3</sup>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly for 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12586628','lexi-content-ref-17938252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12586628','lexi-content-ref-17938252'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> once weekly for 4 weeks followed by maintenance dosing of 375 mg/m<sup>2</sup> once weekly for 4 weeks every 6 months for 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24516013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24516013'])">Ref</a></span>). May be administered as a single agent or in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), or for relapsed disease, in combination with ifosfamide, carboplatin and etoposide (RICE) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24215035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24215035'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abbb788f-5add-4977-917e-976853769656">IgG4-related disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>IgG4-related disease (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Note:</b> IgG4-related disease commonly presents as type 1 (IgG4-related) autoimmune pancreatitis; IgG4-related sclerosing cholangitis; major salivary gland enlargement or sclerosing sialadenitis; orbital disease, often with proptosis; and retroperitoneal fibrosis, frequently with chronic periaortitis. Consider for use in patients who have incomplete response to induction or are unable to sufficiently reduce glucocorticoid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moutsopoulos.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moutsopoulos.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 g once every 15 days for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25667206','lexi-content-ref-28915275','lexi-content-ref-20191576','lexi-content-ref-22210556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25667206','lexi-content-ref-28915275','lexi-content-ref-20191576','lexi-content-ref-22210556'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58acdf8a-6a05-45e7-a020-bd4c6e72f2ed">Immune thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as a single agent for patients who do not have an adequate platelet count response to glucocorticoids. Use in combination with other therapies has also been reported. Optimal dose, frequency, and duration have not been established and vary based on institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17200219','lexi-content-ref-18463354','lexi-content-ref-19846889','lexi-content-ref-31770441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17200219','lexi-content-ref-18463354','lexi-content-ref-19846889','lexi-content-ref-31770441'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3655b5d-39c2-45c7-99f9-ebe4374ded25">Kidney transplant, pretransplant desensitization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney transplant, pretransplant desensitization (adjunctive) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Several institutional protocols exist based on specific targets, anticipated transplant date, and goals of therapy; example regimens for ABO-compatible transplants are provided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27529314','lexi-content-ref-20110854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27529314','lexi-content-ref-20110854'])">Ref</a></span>). Appropriate antiviral and antimicrobial prophylaxis should be employed during and following treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26844479']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26844479'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1 <b>g</b>
<b>once</b> administered 15 to 21 days prior to transplant; in combination with IVIG; with or without plasmapheresis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27529314','lexi-content-ref-20110854','lexi-content-ref-24770617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27529314','lexi-content-ref-20110854','lexi-content-ref-24770617'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e0c96fc2-0d3e-4df6-840a-b53c7931e97e">Lupus nephritis, diffuse or focal, resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lupus nephritis, diffuse or focal, resistant (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in patients who are resistant to initial therapy (eg, glucocorticoids in combination with mycophenolate or cyclophosphamide). May use rituximab in combination with mycophenolate, a calcineurin inhibitor, or cyclophosphamide. Optimal dose, frequency, and duration of therapy are unknown and vary based on institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22032879','lexi-content-ref-Falk.1','lexi-content-ref-19261822','lexi-content-ref-22764193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22032879','lexi-content-ref-Falk.1','lexi-content-ref-19261822','lexi-content-ref-22764193'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 g on days 0 and 15 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22032879','lexi-content-ref-16677395','lexi-content-ref-22764193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22032879','lexi-content-ref-16677395','lexi-content-ref-22764193'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> once weekly for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22032879','lexi-content-ref-19261822','lexi-content-ref-22764193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22032879','lexi-content-ref-19261822','lexi-content-ref-22764193'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9bee352a-a785-40b0-ad2e-1c5883b37b33">Membranous nephropathy, primary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Membranous nephropathy, primary (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used in patients with normal kidney function who are at high or very high risk for progression and select moderate-risk patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DeVriese.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DeVriese.1'])">Ref</a></span>). Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>IV: </b>1 g once every 2 weeks for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31269364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31269364'])">Ref</a></span>); alternative dosing regimens include 375 mg/m<sup>2 </sup>once weekly for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32311997','lexi-content-ref-28487395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32311997','lexi-content-ref-28487395'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> once followed by a second dose of 375 mg/m<sup>2</sup> if ≥5 circulating B cells per mcL are detected by flow cytometry 1 week after the initial dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DeVriese.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DeVriese.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b0eba49-17ba-402d-ac0c-16dea8fe4b60">Minimal change disease, frequently relapsing disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Minimal change disease, frequently relapsing disease (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients with frequently relapsing disease despite glucocorticoid therapy or who are glucocorticoid dependent. Initiate after remission is induced by glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyrier.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyrier.1'])">Ref</a></span>). Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1 g once every 2 weeks for 2 doses; alternative regimens include 375 mg/m<sup>2</sup> once weekly for 4 doses <b>or</b> 375 mg/m<sup>2</sup> once followed by a second dose of 375 mg/m<sup>2</sup> if ≥5 circulating B cells per mcL are detected by flow cytometry 1 week after the initial dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyrier.1','lexi-content-ref-34094516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyrier.1','lexi-content-ref-34094516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="748b3517-cab5-4ccf-a1b6-481705719228">Mixed cryoglobulinemia syndrome, moderate to severe disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mixed cryoglobulinemia syndrome, moderate to severe disease (off-label use):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>IV: </b>1 g once every 2 weeks for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22147661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22147661'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> once weekly for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22147444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22147444'])">Ref</a></span>); usually administer in combination with a systemic glucocorticoid and, if due to HIV or hepatitis B virus infections, with antiviral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fervenza.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fervenza.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4467212e-e3b6-439f-9d05-c9d1aefabbc7">Mucosa-associated lymphoid tissue lymphoma, gastric, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Mucosa-associated lymphoid tissue lymphoma, gastric, advanced (off-label use):</b>
<b>Note: </b>Antihyperuricemic therapy and aggressive hydration are recommended for patients at high risk for tumor lysis syndrome (high tumor burden or lymphocytes ≥25,000/mm<sup>3</sup>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15668468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15668468'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="af40f154-7312-412d-a28e-8e77cdc833ae">Multiple sclerosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Note:</b> Optimal dose, frequency, and duration of therapy have not been established. Dosing regimens vary based on institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1 g once every 2 weeks for 2 doses; then repeat 1 g once every 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32350672','lexi-content-ref-30539030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32350672','lexi-content-ref-30539030'])">Ref</a></span>). Alternatively, may administer 500 mg to 1 g once every 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27760868']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27760868'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4da04af0-48fa-4780-88f0-d4529dc6a8a2">Myasthenia gravis, refractory or muscle-specific tyrosine kinase antibody-positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis, refractory or muscle-specific tyrosine kinase antibody-positive (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Note: </b>Recommended as an early option in patients with muscle-specific tyrosine kinase antibody-positive disease, or in refractory myasthenia gravis when response to other agents is insufficient or limited by toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33144515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33144515'])">Ref</a></span>). Optimal dose, frequency, and duration of therapy have not been established. Dosing regimens vary based on institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>IV:</b> 1 g once every 2 weeks for 2 doses <b>or </b>375 mg/m<sup>2</sup> once weekly for 4 weeks; may repeat full or partial course at preplanned intervals (eg, 6 months) or as clinically indicated based on symptoms and lymphocyte recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33581791','lexi-content-ref-30649616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33581791','lexi-content-ref-30649616'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a872476f-a4cf-4608-9c75-0e1620a2e434">Neuromyelitis optica, relapse prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuromyelitis optica, relapse prevention (alternative therapy) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Note:</b> Optimal dose, frequency, and duration of therapy have not been established. Dosing regimens vary based on institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 g once every 2 weeks for 2 doses <b>or</b> 375 mg/m<sup>2</sup> once weekly for 4 weeks; then repeat 1 g once every 6 months or earlier if CD19+ lymphocytes become detectable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29606320']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29606320'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d4c856e-dedc-4b57-9bc3-4eb783e31618">Non-Hodgkin lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas: Note:</b> Antihyperuricemic therapy and aggressive hydration are recommended for patients at high risk for tumor lysis syndrome (high tumor burden or lymphocytes ≥25,000/mm<sup>3</sup>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Diffuse large B-cell, previously untreated (Rituxan and rituximab biosimilars): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>R-CHOP regimen: </i>
<b>IV:</b> 375 mg/m<sup>2</sup> on day 1 of each chemotherapy cycle for up to 8 doses (in combination with CHOP chemotherapy [or other anthracycline-based regimen]). For patients ≤60 years of age with limited stage aggressive B-cell lymphoma and a favorable prognosis, a randomized trial demonstrated noninferiority with 4 cycles of rituximab-CHOP chemotherapy when compared to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31868632']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31868632'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pola-R-CHP regimen (off-label combination):</i>
<b>IV:</b> 375 mg/m<sup>2</sup> on day 1 every 21 days (in combination with polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone) for 6 cycles, followed by rituximab monotherapy of 375 mg/m<sup>2</sup> on day 1 of cycles 7 and 8 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34904799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34904799'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Diffuse large B-cell, relapsed or refractory (off-label combination): IV:</b> 375 mg/m<sup>2</sup> on day 1 of each 21-day chemotherapy cycle for up to 6 cycles (in combination with bendamustine and polatuzumab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31693429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31693429'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Follicular, CD20-positive, B-cell, previously untreated (Rituxan and rituximab biosimilars):</b>
<b>IV:</b> 375 mg/m<sup>2</sup> on day 1 of each chemotherapy cycle for up to 8 doses (in combination with first-line chemotherapy).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance therapy (as a single agent, in patients with partial or complete response to rituximab plus chemotherapy):<b> Note:</b> Begin 8 weeks after completion of rituximab in combination with chemotherapy.</i>
<b>IV:</b> 375 mg/m<sup>2</sup> once every 8 weeks for 12 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31339826','lexi-content-ref-21176949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31339826','lexi-content-ref-21176949'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonprogressing, low-grade, CD20-positive, B-cell, after 6 to 8 cycles of first-line CVP are completed (Rituxan and rituximab biosimilars): IV:</b> 375 mg/m<sup>2</sup> once weekly for 4 doses every 6 months for a maximum of 16 doses (as a single agent).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Relapsed/Refractory, low-grade or follicular CD20-positive, B-cell (Rituxan and rituximab biosimilars): IV:</b> 375 mg/m<sup>2</sup> once weekly for 4 or 8 doses (as a single agent). Re-treatment following disease progression: 375 mg/m<sup>2</sup> once weekly for 4 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Follicular lymphoma, relapsed (single-agent therapy; off-label dosing): </i>
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly for 4 doses followed by 375 mg/m<sup>2</sup> once every 2 months for 4 additional doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32810220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32810220'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Follicular lymphoma, relapsed/refractory, maintenance therapy (as a single agent, in patients with response to induction therapy; off-label dosing):</i>
<b>IV:</b> 375 mg/m<sup>2</sup> every 3 months until relapse or for maximum duration of 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20439641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20439641'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Follicular lymphoma, relapsed/refractory (off-label combination): </i>
<b>IV:</b> 375 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of cycle 1 (28-day cycle), followed by 375 mg/m<sup>2</sup> on day 1 every 28 days of cycles 2 to 5 (in combination with lenalidomide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30897038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30897038'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rituxan and rituximab biosimilars:</b> Combination therapy with ibritumomab: <b>IV:</b> 250 mg/m<sup>2</sup> IV day 1; repeat in 7 to 9 days with ibritumomab (also see Ibritumomab monograph).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Splenic marginal zone lymphoma (off-label use):</b>
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly for 6 weeks followed by 375 mg/m<sup>2</sup> once every 2 months for 1 to 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23345547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23345547'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> once weekly for 4 weeks as monotherapy or 375 mg/m<sup>2</sup> on day 1 of each chemotherapy cycle for up to 6 cycles; 1 to 2 additional cycles of rituximab monotherapy may be administered for consolidation or to improve response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23016878']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23016878'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f9aefd7-b378-4099-bf36-a1f6c2dc27ea">Pemphigus vulgaris or pemphigus foliaceus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pemphigus vulgaris (labeled use [Rituxan only] for moderate to severe; off-label use for mild) or pemphigus foliaceus (off-label use for mild, moderate, or severe): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Note:</b> Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. May be used alone or as part of an appropriate combination regimen (eg, with systemic glucocorticoid) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32830877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32830877'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dose<b>:</b></i>
<b> IV:</b> 1 g once every 2 weeks for 2 doses, followed by a maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32830877','lexi-content-ref-24500264','lexi-content-ref-28342637','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32830877','lexi-content-ref-24500264','lexi-content-ref-28342637','lexi-content-ref-Manu.1'])">Ref</a></span>). For patients with complete remission who initially presented with severe disease or who have persistently elevated anti-desmoglein (Dsg) antibodies after 3 months, consider another dose of 500 mg to 1 g administered 6 months after initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32830877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32830877'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance dose (if complete remission is achieved with initial therapy): </i>
<b>IV:</b> 500 mg once 12 months after initial therapy, then every 6 months thereafter or based on clinical evaluation, but no sooner than every 16 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24500264','lexi-content-ref-28342637','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24500264','lexi-content-ref-28342637','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment of relapse</i>: <b>Note:</b> Consider in patients whose last rituximab dose was ≥4 to 6 months prior or in patients who did not previously receive rituximab as initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32830877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32830877'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 g once every 2 weeks for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32830877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32830877'])">Ref</a></span>) or 1 g administered as a single dose (manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2db699d8-b484-4743-9770-57a0112e43f4">Posttransplant lymphoproliferative disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttransplant lymphoproliferative disorder (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Note: </b>Used in monomorphic and polymorphic CD20+ disease in conjunction with reduction of immunosuppression. May be used as a single agent or in combination with chemotherapy and/or radiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Negrin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Negrin.1'])">Ref</a></span>). Optimal dose, frequency, and duration of therapy have not been established and vary based on type of lymphoproliferative disease and institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly for 4 doses alone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16254143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16254143'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> once weekly for 4 doses followed 4 weeks later with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22173060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22173060'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="742c866d-624d-41cf-a1cb-742554aedc03">Primary CNS lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary CNS lymphoma (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Newly diagnosed:</i>
<b>IV: </b>375 mg/m<sup>2</sup> on day 3 every 14 days (in combination with high-dose methotrexate) until disease progression or unacceptable toxicity, or for 2 doses beyond a complete response followed by monthly treatments for up to a total of 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24928128']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24928128'])">Ref</a></span>) <b>or</b> 500 mg/m<sup>2</sup> on day 1 of each cycle for 5 to 7 induction cycles (in combination with high-dose methotrexate, vincristine, and procarbazine, followed by whole-brain radiotherapy and cytarabine consolidation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17947720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17947720'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> once per week beginning on day 3 of remission induction and continuing for 6 doses (in combination with high-dose methotrexate, leucovorin, and temozolomide and followed by etoposide and cytarabine consolidation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23569323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23569323'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Refractory disease:</i>
<b>IV: </b>375 mg/m<sup>2</sup> on day 1 every 28 days (in combination with temozolomide) for 4 cycles, followed by temozolomide monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15221999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15221999'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis (Rituxan and rituximab biosimilars) (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Note:</b> For use in patients who have not met treatment goals despite maximally tolerated methotrexate therapy, <b>and </b>either an inadequate response to TNF inhibitor therapy or a history of lymphoproliferative disorder for which rituximab is an approved therapy. May be administered in combination with methotrexate, another conventional synthetic disease-modifying antirheumatic drug, or as monotherapy if other treatment options are not tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34101387']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34101387'])">Ref</a></span>). Patients should be under the care of a clinician experienced with use of rituximab for this condition.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>IV: </b>Initial: 1 g once every 2 weeks for 2 doses; subsequent courses of 1 g once every 2 weeks for 2 doses may be administered every 24 weeks or as indicated based on clinical evaluation, but no sooner than every 16 weeks. <b>Note:</b> In patients who initially respond, may consider a lower dose of 1 g once per subsequent course or 500 mg given twice (2 weeks apart) per course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leandro.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leandro.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1eb22841-5c23-4c27-8f3d-11d4c3f2c666">Thrombotic thrombocytopenic purpura, acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thrombotic thrombocytopenic purpura, acquired (off-label use):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute treatment for initial therapy or for refractory or relapsing disease:</i>
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly for 4 doses, typically in combination with a systemic glucocorticoid and plasma exchange; administer immediately following plasma exchange and allow ≥24 hours after rituximab before the next plasma exchange (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20175870','lexi-content-ref-25784681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20175870','lexi-content-ref-25784681'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylactic therapy during remission (following treatment and recovery from an acute episode) with persistently low ADAMTS13 activity (eg, &lt;20%) but normal platelet count: </i>
<b>Note:</b> The decision to treat prophylactically should be based on shared decision making to consider patient preferences regarding remission versus potential rituximab toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 375 mg/m<sup>2 </sup>once weekly for 1 to 4 doses depending on follow-up measurements of ADAMTS13 activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15933059','lexi-content-ref-George.1','lexi-content-ref-30201758','lexi-content-ref-17233847','lexi-content-ref-21636861','lexi-content-ref-29296757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15933059','lexi-content-ref-George.1','lexi-content-ref-30201758','lexi-content-ref-17233847','lexi-content-ref-21636861','lexi-content-ref-29296757'])">Ref</a></span>). Some experts may administer a single dose of 375 mg/m<sup>2</sup> approximately once every 3 months to maintain remission in patients with multiple relapses and severe ADAMTS13 deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-George.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-George.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="453dc3ca-df1d-4d49-86a6-814a83391a4f">Toxicities associated with immune checkpoint inhibitor therapy, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxicities associated with immune checkpoint inhibitor therapy, treatment (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For treatment of immune-mediated, corticosteroid-refractory dermatologic and hematologic immune mediated adverse events, as well as for immune-mediated encephalitis, myositis, or refractory myasthenia gravis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392','lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 375 mg/m<sup>2 </sup>once weekly for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392','lexi-content-ref-34172516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebda9a81-6b8d-4064-acf9-5c892f36549f">Waldenström macroglobulinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Waldenström macroglobulinemia (off-label use): Note:</b> Antihyperuricemic therapy and aggressive hydration are recommended for patients at high risk for tumor lysis syndrome (high tumor burden or lymphocytes ≥25,000/mm<sup>3</sup>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with cyclophosphamide and dexamethasone:</i>
<b>IV: </b>375 mg/m<sup>2</sup> on day 1 every 21 days for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17577016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17577016'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with cyclophosphamide and fludarabine:</i>
<b>IV: </b>375 mg/m<sup>2</sup> on day 1 every 28 days for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21732338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21732338'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with bortezomib:</i>
<b>IV: </b>375 mg/m<sup>2</sup> on days 1, 8, 15, and 22 every 28 days during cycles 1 and 4; treatment is continued for 6 cycles, with a total of 8 rituximab doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20142586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20142586'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with bortezomib and dexamethasone:</i>
<b>IV: </b>375 mg/m<sup>2</sup> on days 1, 8, 15, and 22 every 35 days during cycles 2 and 5; treatment is administered for 6 cycles, with a total of 8 rituximab doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24004667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24004667'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> on day 11 every 21 days for 4 cycles (induction); after a 12-week break, 4 additional maintenance cycles (spaced 12 weeks apart) were administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19506160']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19506160'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with bendamustine:</i>
<b>IV: </b>375 mg/m<sup>2</sup> on day 1 every 28 days for 4 cycles; single rituximab doses were also administered 1 week prior to the first cycle and 4 weeks after the last cycle (for a total of 6 rituximab doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15908650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15908650'])">Ref</a></span>) <b>or</b> 375 mg/m<sup>2</sup> on day 1 every 28 days for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23433739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23433739'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with carfilzomib and dexamethasone:</i>
<b>IV: </b>375 mg/m<sup>2</sup> on days 2 and 9 every 21 days for 6 induction cycles, followed by 375 mg/m<sup>2</sup> on day 2 every 8 weeks for 8 maintenance cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24859363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24859363'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with ibrutinib:</i>
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly during weeks 1 to 4 and weeks 17 to 20 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29856685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29856685'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="992a0682-8a0f-4293-8ad0-146fa7ebf6a0">Warm autoimmune hemolytic anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Warm autoimmune hemolytic anemia (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Note:</b> Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>IV:</b> 375 mg/m<sup>2</sup> once weekly for 4 doses in combination with a systemic glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23981017','lexi-content-ref-21981575','lexi-content-ref-31839434','lexi-content-ref-25497766','lexi-content-ref-24847759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23981017','lexi-content-ref-21981575','lexi-content-ref-31839434','lexi-content-ref-25497766','lexi-content-ref-24847759'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991247"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Kidney impairment prior to treatment initiation:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Theoretically, rituximab’s large molecular weight (145,000 Daltons) precludes the drug from being efficiently filtered at the glomerulus or by dialysis filters; hence, in general, dose adjustments for kidney dysfunction and/or renal replacement therapies should be unnecessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22232754','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22232754','lexi-content-ref-Expert.DOR'])">Ref</a></span>). In patients with nephrotic syndrome, urinary rituximab losses and altered pharmacokinetics have been observed, but the dosing implications of these findings are uncertain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30293439','lexi-content-ref-28243475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30293439','lexi-content-ref-28243475'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b>
<b>IV:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26458604','lexi-content-ref-18589184','lexi-content-ref-12072308','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26458604','lexi-content-ref-18589184','lexi-content-ref-12072308','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12410580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12410580'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment or supplemental dose necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17988304','lexi-content-ref-12410580','lexi-content-ref-20930448','lexi-content-ref-26689650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17988304','lexi-content-ref-12410580','lexi-content-ref-20930448','lexi-content-ref-26689650'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis: </b>In general, unlikely to be significantly dialyzed (expert opinion); however, significant amounts reported to be dialyzed in a patient with nephrotic syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28243475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28243475'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22382230','lexi-content-ref-23124537','lexi-content-ref-23645657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22382230','lexi-content-ref-23124537','lexi-content-ref-23645657'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31271628','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31271628','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988497"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F56432558"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatitis B virus reactivation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<b>Exacerbation of </b>hepatitis B virus </b>(HBV) may occur in patients treated with rituximab, in some cases resulting in <b>fulminant hepatitis</b>, <b>hepatic failure</b>, and death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22967460','lexi-content-ref-28983798','lexi-content-ref-27471722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22967460','lexi-content-ref-28983798','lexi-content-ref-27471722'])">Ref</a></span>). Reactivation has occurred in patients who are hepatitis B surface antigen (HBsAg) positive (typical reactivation) as well as in those who are HBsAg negative but are anti-HBc positive (reverse seroconversion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20002298','lexi-content-ref-32716741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20002298','lexi-content-ref-32716741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: In the immune system control of HBV infection, B-cells may act as antigen-presenting cells and prime cytotoxic T-cells for lysis of HBV-infected hepatocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20807092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20807092'])">Ref</a></span>). Rituximab causes B-cell depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22967460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22967460'])">Ref</a></span>), which therefore may impair control of HBV infection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; may occur months to years after cessation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20002298','lexi-content-ref-32716741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20002298','lexi-content-ref-32716741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic HBV (HBsAg positive) or past HBV (HBsAg negative and anti-HBc positive with either negative or positive anti-HBs) infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32716741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32716741'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hematologic malignancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32716741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32716741'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of stem cell transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32716741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32716741'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of other risk factor for HBV infection (eg, high-prevalence region, household contact, high-risk behavior) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30892921']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30892921'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypogammaglobulinemia and Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, including fatal, bacterial, fungal, and new or reactivated viral <b>infections </b>can occur during and following the completion of rituximab-based therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16947627','lexi-content-ref-24778295','lexi-content-ref-28983798','lexi-content-ref-20110520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16947627','lexi-content-ref-24778295','lexi-content-ref-28983798','lexi-content-ref-20110520'])">Ref</a></span>). Infections have been reported in some patients with prolonged <b>hypogammaglobulinemia</b>. New or reactivated viral infections have included <b>CMV viremia</b>, <b>herpes simplex infection</b>, <b>parvovirus B19 seroconversion</b>, <b>varicella zoster infection</b>, West Nile virus, and <b>hepatitis C</b> and B.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; immunosuppression due to B-cell depletion, hypogammaglobulinemia, and neutropenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24778295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24778295'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; infection may occur at any time; risk may be higher in the 3 to 6 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28800262'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Hypogammaglobulinemia:</p>
<p style="text-indent:-2em;margin-left:8em;">• More than 1 dose of rituximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Maintenance regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Low pre-treatment immunoglobulin levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Exposure to mycophenolate or purine analogues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection:</p>
<p style="text-indent:-2em;margin-left:8em;">• Malignant versus non-malignant indications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30646343','lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30646343','lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher number of rituximab courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Prolonged low levels of IgG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• G-CSF use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Glucocorticoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30646343','lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30646343','lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Chronic lung disease and/or cardiac insufficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30646343','lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30646343','lexi-content-ref-28800262'])">Ref</a></span>)</p>
<p style="text-indent:0em;margin-left:6em;">• Extra-articular involvement in patients with rheumatic arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30646343','lexi-content-ref-28800262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30646343','lexi-content-ref-28800262'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infusion-related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious (including fatal) infusion-related reactions have been reported with rituximab. Reactions may include <b>angioedema</b>, <b>bronchospasm</b>, <b>cough</b>, <b>hypotension</b>, <b>hypoxia</b>, <b>throat irritation</b>, <b>urticaria</b>, and in more severe cases, <b>acute respiratory distress syndrome</b>, <b>pulmonary infiltrates</b>, <b>acute myocardial infarction</b>, <b>ventricular fibrillation</b>, and <b>cardiogenic shock</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22967460','lexi-content-ref-17522249']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22967460','lexi-content-ref-17522249'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; may produce human antichimeric antibodies and human antihuman antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17522249']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17522249'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; usually occur within 30 to 120 minutes after starting the infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• First infusion (~80% of fatal infusion reactions occurred in association with the first infusion)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22967460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22967460'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High tumor burden with treatment-sensitive malignant disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17522249','lexi-content-ref-10498591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17522249','lexi-content-ref-10498591'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of prior cardiopulmonary reactions</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cardiac or pulmonary conditions</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Progressive multifocal leukoencephalopathy (PML)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Progressive multifocal leukoencephalopathy</b> (PML) due to John Cunningham (JC) virus infection has been reported with rituximab and may be fatal<b>. </b>Cases were reported in patients with hematologic malignancies receiving rituximab either with combination chemotherapy or with hematopoietic stem cell transplant. Cases were also reported in patients receiving rituximab for autoimmune diseases who had received concurrent or prior immunosuppressant therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22422012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22422012'])">Ref</a></span>). Clinical findings included confusion/disorientation, motor weakness/hemiparesis, altered vision/speech, and poor motor coordination with symptoms progressing over weeks to months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19347724','lexi-content-ref-22422012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19347724','lexi-content-ref-22422012'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; reactivation of the JC virus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19347724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19347724'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; most cases were diagnosed within 12 months of the last rituximab dose. A retrospective analysis of patients (n=57) diagnosed with PML following rituximab therapy found a median of 16 months (following rituximab initiation), 5.5 months (following last rituximab dose), and six rituximab doses preceded PML diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19347724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19347724'])">Ref</a></span>). In a series of rheumatologic cases, a median of 12 months (range 1 to 57 months following rituximab initiation), and 5 months (range 0 to 29 months following last rituximab dose), and two rituximab courses preceded PML diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22422012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22422012'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Systemic lupus erythematosus (SLE) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22422012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22422012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Undiagnosed HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22422012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22422012'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F218815"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Patients treated with rituximab for rheumatoid arthritis (RA) may experience fewer adverse reactions. Most reported adverse reactions are from studies in which rituximab was given concomitantly with chemotherapeutic agents, glucocorticoid steroids, or methotrexate. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac disorder (5% to 29%), flushing (5% to 14%), hypertension (6% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypertension')">table 1</a>)</span><span class="table-link" style="display:none;">Hypertension</span>, peripheral edema (8% to 16%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypertension" frame="border" id="lexi-content-hypertension" rules="all">
<caption style="text-align:center;">
<b>Rituximab: Adverse Reaction: Hypertension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cyclophosphamide plus glucocorticoids: 5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Granulomatosis with polyangiitis and microscopic polyangiitis; induction therapy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus glucocorticoids</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Most patients received 375 mg/m² weekly for 4 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell, non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Placebo plus methotrexate: 5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 x 1,000 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">540</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus methotrexate</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Night sweats (15%), pruritus (≤17%)<span class="lexi-table-link-container"> (<a aria-label="Pruritus table link" class="lexi-table-link" data-table-id="lexi-content-pruritus" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pruritus')">table 2</a>)</span><span class="table-link" style="display:none;">Pruritus</span>, skin rash (≤17%)<span class="lexi-table-link-container"> (<a aria-label="Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-rash')">table 3</a>)</span><span class="table-link" style="display:none;">Skin Rash</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pruritus" frame="border" id="lexi-content-pruritus" rules="all">
<caption style="text-align:center;">
<b>Rituximab: Adverse Reaction: Pruritus</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No further therapy: 5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 4 doses every 6 months for up to 16 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated, low-grade or follicular, CD-20 positive, B-cell, non-Hodgkin lymphoma, maintenance therapy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">In patients who did not progress after 6 to 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP); described as "rash and/or pruritus"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cyclophosphamide, vincristine, prednisone (CVP): 1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated, low-grade or follicular, CD-20 positive, B-cell, non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Most patients received 375 mg/m<sup>2</sup> weekly for 4 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory, low-grade or follicular, CD-20 positive, B-cell, non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Placebo plus methotrexate: 1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 x 1,000 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">540</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus methotrexate</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Rash" frame="border" id="lexi-content-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Rituximab: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cyclophosphamide plus glucocorticoids: 17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Granulomatosis with polyangiitis and microscopic polyangiitis; induction therapy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus glucocorticoids</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cyclophosphamide, vincristine, and prednisone (CVP): 5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated, low-grade or follicular, CD-20 positive, B-cell, non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No further therapy: 5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 4 doses every 6 months for up to 16 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated, low-grade or follicular, CD-20 positive, B-cell, non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">In patients who did not progress after 6 to 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP); described as "rash and/or pruritus"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Most patients received 375 mg/m² weekly for 4 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory, low-grade or follicular, CD-20 positive, B-cell non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypophosphatemia (12% to 21%), weight gain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (14%), diarrhea (10% to 17% grades 3/4: 1%), nausea (8% to 23%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (8% to 35%; grades 3/4: 3%), febrile neutropenia (grades 3/4: 9% to 15%), hypogammaglobulinemia (&lt;1% to 58%; including IgA, IgG, or IgM below the lower limit of normal, can be prolonged)<span class="lexi-table-link-container"> (<a aria-label="Hypogammaglobulinemia table link" class="lexi-table-link" data-table-id="lexi-content-hypogammaglobulinemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypogammaglobulinemia')">table 4</a>)</span><span class="table-link" style="display:none;">Hypogammaglobulinemia</span>, leukopenia (10% to 14%; grades 3/4: 4% to 23%), lymphocytopenia (48%; grades 3/4: 40%), neutropenia (8% to 14%; grades 3/4: 4% to 49%; may be prolonged neutropenia [lasting up to 42 days] or late onset [occurring &gt;42 days after last dose]), thrombocytopenia (12%; grades 3/4: 2% to 11%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypogammaglobulinemia" frame="border" id="lexi-content-hypogammaglobulinemia" rules="all">
<caption style="text-align:center;">
<b>Rituximab: Adverse Reaction: Hypogammaglobulinemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">58%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cyclophosphamide plus glucocorticoids: 50%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Granulomatosis with polyangiitis and microscopic polyangiitis; induction therapy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus glucocorticoids; Low IgG level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">51%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cyclophosphamide plus glucocorticoids: 46%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Granulomatosis with polyangiitis and microscopic polyangiitis; induction therapy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus glucocorticoids; Low IgM level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cyclophosphamide plus glucocorticoids: 25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Granulomatosis with polyangiitis and microscopic polyangiitis; induction therapy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus glucocorticoids; Low IgA level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mycophenolate mofetil (MMF) plus oral corticosteroids: N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,000 mg on days 1, 15, week 24, and week 26 for up to 52 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pemphigus vulgaris</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">67</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus oral corticosteroids; prolonged hypogammaglobulinemia (defined as Ig levels below lower limit of normal for at least 4 months); IgG or IgM</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Placebo plus methotrexate: N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 x 1,000 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">540</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus methotrexate; Low IgM level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Placebo plus methotrexate: N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 x 1,000 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">540</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus methotrexate; Low IgG level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Placebo plus methotrexate: N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 x 1,000 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">540</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus methotrexate; Low IgA level</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatobiliary disease (17%), increased serum alanine aminotransferase (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (1% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacterial infection (19%; including cellulitis), infection (19% to 63%%; including CMV viremia, herpes simplex infection, parvovirus B19 seroconversion, varicella zoster infection, hepatitis C, and lower respiratory tract infection)<span class="lexi-table-link-container"> (<a aria-label="Infection table link" class="lexi-table-link" data-table-id="lexi-content-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infection')">table 5</a>)</span><span class="table-link" style="display:none;">Infection</span>, serious infection (2% to 11%; including sepsis)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infection" frame="border" id="lexi-content-infection" rules="all">
<caption style="text-align:center;">
<b>Rituximab: Adverse Reaction: Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">62%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cyclophosphamide plus glucocorticoids: 47%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Granulomatosis with polyangiitis and microscopic polyangiitis; induction therapy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus glucocorticoids</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">63%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mycophenolate mofetil (MMF) plus oral corticosteroids: N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,000 mg on days 1, 15, week 24, and week 26 for up to 52 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pemphigus vulgaris</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">67</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus oral corticosteroids</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">37%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Observation: 22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 8 weeks for up to 12 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated, low-grade or follicular, CD-20 positive, B-cell, non-Hodgkin lymphoma; maintenance therapy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initiated 8 weeks following completion of chemotherapy in patients who achieved a response with rituximab plus chemotherapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No further therapy: 9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 4 doses every 6 months for up to 16 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated, low-grade or follicular, CD-20 positive, B-cell, non-Hodgkin lymphoma; maintenance therapy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">In patients who did not progress after 6 to 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Most patients received 375 mg/m² weekly for 4 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory, low-grade or follicular, CD-20 positive, B-cell, non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Placebo plus methotrexate: 34%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 x 1,000 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">540</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus methotrexate</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (3% to 33%), fatigue (13% to 39%), headache (15% to 19%), insomnia (14%), pain (12%), peripheral sensory neuropathy (30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (6% to 13%), asthenia (2% to 26%), muscle spasm (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, cough (13% to 15%)<span class="lexi-table-link-container"> (<a aria-label="Cough table link" class="lexi-table-link" data-table-id="lexi-content-cough" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cough')">table 6</a>)</span><span class="table-link" style="display:none;">Cough</span>, epistaxis (11%), nasopharyngitis (≤16%), pulmonary disease (31%), pulmonary toxicity (18%), rhinitis (3% to 12%), upper respiratory tract infection (≤16%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cough" frame="border" id="lexi-content-cough" rules="all">
<caption style="text-align:center;">
<b>Rituximab: Adverse Reaction: Cough</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cyclophosphamide plus glucocorticoids: 11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Granulomatosis with polyangiitis and microscopic polyangiitis; induction therapy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus glucocorticoids</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cyclophosphamide, vincristine, and prednisone (CVP): 6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated, low-grade or follicular, CD20-positive, B-cell, non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Most patients received 375 mg/m² weekly for 4 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory, low-grade or follicular, CD-20 positive, B-cell, non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (5% to 56%), infusion related reaction (first dose: 12% to 77%; including cytokine release syndrome and nonimmune anaphylaxis; reactions can be acute; decreases with subsequent infusions)<span class="lexi-table-link-container"> (<a aria-label="Infusion Related Reaction table link" class="lexi-table-link" data-table-id="lexi-content-infusion-related-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infusion-related-reaction')">table 7</a>)</span><span class="table-link" style="display:none;">Infusion Related Reaction</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infusion Related Reaction" frame="border" id="lexi-content-infusion-related-reaction" rules="all">
<caption style="text-align:center;">
<b>Rituximab: Adverse Reaction: Infusion Related Reaction</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">59%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fludarabine plus cyclophosphamide (FC): N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² as an initial infusion, followed by 500 mg/m² for up to 5 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Chronic lymphocytic leukemia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus fludarabine and cyclophosphamide (R-FC)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cyclophosphamide plus glucocorticoids: 11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">375 mg/m² once weekly for 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Granulomatosis with polyangiitis and microscopic polyangiitis; induction therapy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus glucocorticoids</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">77%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First infusion</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,000 mg on days 1, 15, week 24, and week 26 for up to 52 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pemphigus vulgaris</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">67</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Placebo plus methotrexate: 23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 x 1,000 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">540</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus methotrexate</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest tightness (7%), hypotension (10%), significant cardiovascular event (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (2% to 8%)<span class="lexi-table-link-container"> (<a aria-label="Urticaria table link" class="lexi-table-link" data-table-id="lexi-content-urticaria" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-urticaria')">table 8</a>)</span><span class="table-link" style="display:none;">Urticaria</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Urticaria" frame="border" id="lexi-content-urticaria" rules="all">
<caption style="text-align:center;">
<b>Rituximab: Adverse Reaction: Urticaria</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Most patients received 375 mg/m² weekly for 4 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory, low-grade or follicular, CD-20 positive, B-cell, non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Placebo plus methotrexate: &lt;1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 x 1,000 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">540</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus methotrexate</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (9%), hyperuricemia (2%), increased lactate dehydrogenase (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (3%), oral candidiasis (9%), upper abdominal pain (2%), vomiting (10%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Pancytopenia (grades 3/4: 3%; can be prolonged)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Exacerbation of hepatitis B (grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (1%), viral infection (10%; including herpes zoster)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (2% to 5%), dizziness (6% to 10%), migraine (2%), paresthesia (2%), rigors (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (9% to 10%), myalgia (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (8%), dyspnea (7% to 10%), sinusitis (6%), throat irritation (2% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Throat Irritation table link" class="lexi-table-link" data-table-id="lexi-content-throat-irritation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-throat-irritation')">table 9</a>)</span><span class="table-link" style="display:none;">Throat Irritation</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Throat Irritation" frame="border" id="lexi-content-throat-irritation" rules="all">
<caption style="text-align:center;">
<b>Rituximab: Adverse Reaction: Throat Irritation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rituximab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Most patients received 375 mg/m² weekly for 4 doses</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory, low-grade or follicular, CD-20 positive, B-cell, non-Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Placebo plus methotrexate: 0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 x 1,000 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">540</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rituximab plus methotrexate</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic &amp; oncologic: Hemolytic anemia, pure red cell aplasia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Kasi 2012), cardiac tamponade (Cohen 2006), cardiogenic shock (Kasi 2012), heart failure (Kasi 2012), Kawasaki syndrome (Sato 2020), myocarditis (Ghielmini 2004), vasculitis (systemic; with rash) (Kim 2009), ventricular fibrillation (Kasi 2012), ventricular tachycardia (Kasi 2012),</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Epidermolysis bullosa (Wu 2020), lichenoid dermatitis (Scheinfeld 2006), pemphigus (paraneoplastic) (Scheinfeld 2006), pyoderma gangrenosum (including genital presentation) (Georgakopoulos 2018, Maloney 2018), Stevens-Johnson syndrome (Scheinfeld 2006), toxic epidermal necrolysis (Scheinfeld 2006), vesiculobullous dermatitis (Scheinfeld 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Crohn’s disease (Cavalcanti 2020), enterocolitis (including ileocolitis, ulcerative colitis, microscopic colitis) (Tsuzuki 2021), intestinal obstruction (Kasi 2012), intestinal perforation (mean onset: 6 days [range: 1 to 77 days in patients with non-Hodgkin lymphoma]) (Cornejo 2009, Kollmar 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression (Kasi 2012), increased serum immunoglobulins (hyperviscosity syndrome in Waldenström's macroglobulinemia), Kaposi sarcoma (including new onset and progression) (Billon 2018, Geller 2018), sarcoidosis (children: Scar sarcoidosis) (Vesely 2020), tumor lysis syndrome (Yang 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Fulminant hepatitis (Evens 2011), hepatic failure (Evens 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Liccioli 2020), serum sickness (Fouda 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Reactivation of HBV (Evens 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Progressive multifocal leukoencephalopathy (Carson 2009, Molloy 2012), reversible posterior leukoencephalopathy syndrome (Mustafa 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (polyarticular), lupus-like syndrome (Chessa 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis, uveitis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome (Kasi 2012), bronchiolitis obliterans (Shen 2012), hypoxia (Kasi 2012), interstitial pulmonary disease (Wagner 2007), pleurisy, pneumonia, pulmonary infiltrates (Kasi 2012)</p></div>
<div class="block coi drugH1Div" id="F218829"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Known type 1 hypersensitivity or anaphylactic reaction to murine proteins, Chinese Hamster Ovary (CHO) cell proteins, or any component of the formulation; patients who have or have had progressive multifocal leukoencephalopathy (PML); patients with severe, active infections</p></div>
<div class="block war drugH1Div" id="F218812"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bowel obstruction/perforation: Abdominal pain, bowel obstruction, and perforation have been reported (rarely fatal), with an average onset of symptoms of ~6 days (range: 1 to 77 days); evaluate abdominal pain or repeated vomiting.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cytopenias: Rituximab is associated with lymphopenia, leukopenia, neutropenia, thrombocytopenia, and anemia; the duration of cytopenias may be prolonged and may extend months beyond treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: May cause fatal renal toxicity in patients with non-Hodgkin lymphomas (NHL). Patients who received combination therapy with cisplatin and rituximab for NHL experienced renal toxicity during clinical trials; this combination is not an approved treatment regimen. Renal toxicity also occurred due to tumor lysis syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome leading to acute renal failure requiring dialysis (sometimes fatal) may occur within 12 to 24 hours following the first dose when used as a single agent in the treatment of NHL. Hyperkalemia, hypocalcemia, hyperuricemia, and/or hyperphosphatemia may occur. Administer prophylaxis (antihyperuricemic therapy, aggressive hydration) in patients at high risk (high numbers of circulating malignant cells ≥25,000/mm<sup>3</sup> or high tumor burden). Correct electrolyte abnormalities and administer supportive care as indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Granulomatosis with polyangiitis/microscopic polyangiitis: The safety of concomitant immunosuppressants other than corticosteroids has not been evaluated in patients with granulomatosis with polyangiitis or microscopic polyangiitis after rituximab-induced B-cell depletion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: There is a higher risk of cardiac (supraventricular arrhythmia) and pulmonary adverse events (pneumonia, pneumonitis), and the incidence of grade 3 or 4 adverse reactions are higher in patients ≥65 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold biologic disease-modifying antirheumatic drugs (DMARDs) prior to surgery and plan surgery after the next dose is due. Surgery can occur after holding medication for 1 full dosing cycle (eg, for medications administered every 4 weeks, schedule surgery 5 weeks from last administered dose); therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk). Decisions to withhold therapy should be based on shared decision making; ensure the patient and their provider weigh risks of interrupting therapy and disease control versus risks of continuing therapy and surgical complications (ACR/AAHKS [Goodman 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pemphigus vulgaris: The safety of concomitant immunosuppressants other than corticosteroids has not been evaluated in patients with pemphigus vulgaris after rituximab-induced B-cell depletion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rheumatoid arthritis: There are limited data on the safety of other biologics or DMARDs other than methotrexate in patients with rheumatoid arthritis (RA) with B-cell depletion following rituximab treatment. Monitor patients closely for infection if biologic agents or DMARDs are used concomitantly. The use of rituximab is not recommended in RA patients who have not had prior inadequate response to one or more tumor necrosis factor antagonists.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Rituximab is for IV administration only. Do not substitute rituximab and hyaluronidase (SUBQ) for rituximab (IV). Use caution during product selection, preparation, and administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: In the oncology setting, live vaccines should not be given before or during rituximab treatment; the safety of live vaccines following rituximab treatment has not been studied. When using for the treatment of multiple sclerosis, avoid live-attenuated vaccines in patients who currently receive or have recently discontinued rituximab; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]). Review vaccination status for all patients, and if possible, bring up to date with all immunizations (following current immunization guideline recommendations) prior to rituximab initiation and administer nonlive vaccines at least 4 weeks prior to initiating a rituximab course of therapy. Response to some immunizations may be lower in some patients receiving rituximab.</p></div>
<div class="block foc drugH1Div" id="F218822"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Riabni: rituximab-arrx 100 mg/10 mL (10 mL); rituximab-arrx 500 mg/50 mL (50 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rituxan: 100 mg/10 mL (10 mL [DSC]); 10 mg/mL (10 mL, 50 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ruxience: rituximab-pvvr 100 mg/10 mL (10 mL); rituximab-pvvr 500 mg/50 mL (50 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Truxima: rituximab-abbs 100 mg/10 mL (10 mL); rituximab-abbs 500 mg/50 mL (50 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F218808"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F6133643"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Riabni Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/10 mL (per mL): $86.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/50 mL (per mL): $86.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Rituxan Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/10 mL (per mL): $112.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/50 mL (per mL): $112.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ruxience Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/10 mL (per mL): $86.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/50 mL (per mL): $86.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Truxima Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/10 mL (per mL): $101.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/50 mL (per mL): $101.47</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868175"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Riabni: 10 mg/mL (10 mL, 50 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rituxan: 10 mg/mL (10 mL, 50 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Riximyo: 10 mg/mL (10 mL, 50 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ruxience: 10 mg/mL (10 mL, 50 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Truxima: 100 mg/10 mL (10 mL); 500 mg/50 mL (50 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52613825"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV infusion: Must be diluted prior to administration; do not administer undiluted or as an IV push or rapid injection. Premedicate with acetaminophen, an antihistamine, with/without corticosteroid as indicated. For oncology uses in pediatric patients, in addition to prednisone which is part of the chemotherapeutic regimen, premedicate 30 to 60 minutes prior to the rituximab infusion with acetaminophen and an H<sub>1</sub> antihistamine (eg, diphenhydramine). For granulomatosis with polyangiitis, microscopic polyangiitis, and Wegener granulomatosis, in addition to an antihistamine and acetaminophen, patients should also be premedicated 30 minutes prior to each infusion with methylprednisolone (eg, 100 mg IV in adults or equivalent).</p>
<p style="text-indent:-2em;margin-left:2em;">In pediatric trials, described infusion rates vary and are indication specific. One retrospective report (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29042839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29042839'])">Ref</a></span>) evaluated rituximab infusion in 67 pediatric patients for multiple uses (mostly autoimmune disease [58%] and oncology uses [36%]) and used a 2 mg/mL concentration. In the trial, patients were premedicated with intravenous diphenhydramine (1 mg/kg up to 50 mg/dose) and oral acetaminophen (10 mg/kg up to 650 mg/dose); corticosteroid premedication was at prescriber discretion. Overall, infusions were well tolerated; 5 (2.7% incidence) infusion related reactions were reported and were grade 1 or 2 severity). Infusions were administered with the following:</p>
<p style="text-indent:-2em;margin-left:4em;">First dose: Initial rate: 0.5 mg/kg/hour (maximum rate: 50 mg/hour) for 1 hour; if tolerated, then rate increase in 0.5 mg/kg/hour increments every 30 minutes up to a maximum 400 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29042839','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29042839','lexi-content-ref-Manu.1'])">Ref</a></span>). If hypersensitivity or infusion-related reactions occur, slow or interrupt the infusion. If symptoms completely resolve, resume infusion at 50% of the previous rate.</p>
<p style="text-indent:-2em;margin-left:4em;">Subsequent doses (if first dose well tolerated): Initial rate: 1 mg/kg/hour (maximum rate: 50 mg/hour [per the manufacturer]; 100 mg/hour has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29042839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29042839'])">Ref</a></span>)) for 1 hour; if tolerated, then increase rate in 1 mg/kg/hour increments every 30 minutes up to a maximum 400 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29042839','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29042839','lexi-content-ref-Manu.1'])">Ref</a></span>). If hypersensitivity or infusion-related reactions occur, slow or interrupt the infusion. If symptoms completely resolve, resume infusion at 50% of the previous rate.</p>
<p style="text-indent:-2em;margin-left:4em;">Refer to specific protocols for administration rate guidelines.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Indication-specific information:</i> Limited data available: Infusion data reported from experience in pediatric trials. If hypersensitivity or infusion-related reactions occur, slow or interrupt the infusion. If symptoms completely resolve, resume infusion at 50% of the previous rate (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">Acute leukemia: 0.5 mg/kg/hour for the first hour; if tolerated, rate was increased every 30 minutes to maximum rate of 400 mg/hour in trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22940833','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22940833','lexi-content-ref-Manu.1'])">Ref</a></span>); in some oncology trials, doses were infused over 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23823112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23823112'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Autoimmune hemolytic anemia: Doses were infused over 5 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12531800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12531800'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Granulomatosis with polyangiitis and microscopic polyangiitis: <b>Note:</b> Although an FDA-approved indication, administration to pediatric patients is not described in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:8em;">Initial infusions: In the clinical trial (n=25, age range: 6 to 17 years), infusions were initiated at a rate of 25 mg/hour. If no hypersensitivity or infusion-related reactions occurred, infusion rates were increased in 25 mg/hour increments every 30 minutes to a maximum infusion rate of 200 mg/hour as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NCT01750697.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NCT01750697.1'])">Ref</a></span>). <b>Note:</b> In the clinical trial utilizing these rates of administration, the youngest patient enrolled was 6 years of age.</p>
<p style="text-indent:-2em;margin-left:6em;">Nephrotic syndrome: Doses were infused over 3 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20798255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20798255'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Non-Hodgkin lymphoma: 0.5 mg/kg/hour for the first hour; if tolerated, rate was increased every 30 minutes to maximum rate of 400 mg/hour in trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22940833','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22940833','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Posttransplant lymphoproliferative disorder: Doses were infused over 2 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10707791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10707791'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Systemic lupus erythematosus: Doses of 187.5 mg/m<sup>2</sup> were infused over 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18097688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18097688'])">Ref</a></span>); doses of 375 mg/m<sup>2</sup> were infused over 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18097688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18097688'])">Ref</a></span>); the infusion time of the higher 750 mg/m<sup>2</sup> doses was not reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Rapid rate infusions: </i>Children and Adolescents: Multiple regimens have been reported and most experience reported with nononcologic uses of rituximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26583612','lexi-content-ref-29042839','lexi-content-ref-26205134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26583612','lexi-content-ref-29042839','lexi-content-ref-26205134'])">Ref</a></span>). <b>Note:</b> Rapid infusion rates should not be used for initial infusions, in unstable patients, patients at risk for tumor lysis syndrome or with an absolute lymphocyte count &gt;5,000/mm<sup>3</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26583612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26583612'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">90-minute infusion: IV: Infuse 20% of the dose over the first 30 minutes; if tolerated, increase rate to deliver the remaining 80% of the dose over 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26583612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26583612'])">Ref</a></span>). Infusion protocol reported in 17 pediatric and young adult patients (age range: 2 to 23 years of age) for 37 infusions (majority of doses were 375 mg/m<sup>2</sup>); patients were premedicated with diphenhydramine and acetaminophen (doses not reported); concentration of infusion not reported. The results showed one grade 1 infusion related reaction (hypotension) in a single patient who also took amlodipine on the morning prior to infusion (which was not recommended) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26583612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26583612'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">60-minute infusion: Reported only in nononcologic uses and for doses of 375 mg/m<sup>2</sup>: IV: Infuse dose over 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26205134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26205134'])">Ref</a></span>). Infusion protocol reported in 20 pediatric patients (mean age: 10.2 years; range: 4 months to 14 years) for 64 pediatric infusions with mostly autoimmune cytopenias, Epstein-Barr viremia, and graft-vs-host disease; patients were premedicated with diphenhydramine and acetaminophen (doses not reported); corticosteroids were administered according to clinician discretion and protocols (4 of the 20 patients did not receive corticosteroids nor have infusion-related reactions); 2 adverse events were observed; 1 resolved and the other lead to therapy discontinuation; concentration of infusion not reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26205134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26205134'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F218826"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Refer to specific protocol for administration rate guidelines.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV administration only. Do <b>not</b> administer IV push or bolus. Do not administer IV rituximab subcutaneously. If an infusion-related reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate. Discontinue infusion in the event of serious or life-threatening cardiac arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial infusion: Start infusion at a rate of 50 mg/hour; if there is no infusion-related reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Subsequent infusions:</p>
<p style="text-indent:-2em;margin-left:6em;">Standard infusion rate: If patient tolerated initial infusion, start at 100 mg/hour; if there is no infusion-related reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour.</p>
<p style="text-indent:-2em;margin-left:6em;">Accelerated infusion rate (90 minutes): For adult patients with previously untreated follicular NHL and diffuse large B-cell NHL who are receiving a corticosteroid as part of their combination chemotherapy regimen, have a circulating lymphocyte count &lt;5,000/mm<sup>3</sup>, or have no significant cardiovascular disease. After tolerance has been established (no grade 3 or 4 infusion-related event) at the recommended infusion rate in cycle 1, a rapid infusion rate may be used beginning with cycle 2. The daily corticosteroid, acetaminophen, and diphenhydramine are administered prior to treatment, then the rituximab dose is administered over 90 minutes, with 20% of the dose administered over the first 30 minutes and the remaining 80% is given over 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17244675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17244675'])">Ref</a></span>). If the 90-minute infusion in cycle 2 is tolerated, the same rate may be used for the remainder of the treatment regimen (through cycles 6 or 8).</p></div>
<div class="block sts drugH1Div" id="F218838"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Storage time varies by product; refer to individual product labeling for details.</p>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials at 2°C to 8°C (36°F to 46°F); do not freeze. Do not shake. Protect vials from direct sunlight.</p>
<p style="text-indent:-2em;margin-left:4em;">Rituxan, Truxima: Solutions diluted for infusion in NS or D5W may be stored at 2°C to 8°C (36°F to 46°F) for 24 hours and are stable at room temperature for an additional 24 hours (Rituxan or Truxima), although because there is no preservative, the manufacturers recommend storing refrigerated.</p>
<p style="text-indent:-2em;margin-left:4em;">Riabni: If not used immediately, solutions diluted for infusion in NS may be stored at 2°C to 8°C (36°F to 46°F) for 7 days and solutions diluted for infusion in D5W may be stored at 2°C to 8°C (36°F to 46°F) for up to 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Ruxience: If not used immediately, solutions diluted for infusion in NS may be stored at 2°C to 8°C (36°F to 46°F) for up to 16 days and solutions diluted for infusion in D5W may be stored at 2°C to 8°C (36°F to 46°F) for up to 24 hours.</p></div>
<div class="block meg drugH1Div" id="F7882123"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Riabni: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F761140s001lbl.pdf%23page%3D41&amp;token=ulo3Pb7a4nMGQvL5LKjdkfJ1QiqdcUOVavfoFx5eOL4bznKt8slGyUZtuEi6g3xJ7Y6oKYXAigXj%2FcKiy3be5pNKSX%2BeF2yLXLGGSATPFFV8abWhlYA%2BN6VMJH8xZ1ef&amp;TOPIC_ID=12971" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761140s001lbl.pdf#page=41</a></p>
<p style="text-indent:-2em;margin-left:4em;">Rituxan: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F103705s5465lbl.pdf%23page%3D56&amp;token=3zPGcUDObju2ZDW7hIg%2FAk45R64%2FzyxtrcSHg0ukT%2BK%2BFhpetrC3OXsg0syHTwZ6xgVFrxxIGviF7LR%2BUL5V4%2F%2FmytOE3qecBfHtxfZ04OEv76gujl4KMa6j%2B2C67vJT&amp;TOPIC_ID=12971" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5465lbl.pdf#page=56</a></p>
<p style="text-indent:-2em;margin-left:4em;">Ruxience: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761103s011lbl.pdf%23page%3D42&amp;token=yYZOb8%2FR%2Ffu3IPn1MCtDMfJ1QiqdcUOVavfoFx5eOL6yAcUgmiOC4%2FS1hOggzlVN29UXym5M4vM1isPSJOPONS0dg%2FrGEZeTWt7uuFGf9bE9osWO%2BSmYkUY1VQUTAcV6&amp;TOPIC_ID=12971" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761103s011lbl.pdf#page=42</a></p>
<p style="text-indent:-2em;margin-left:4em;">Truxima: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F761088s018lbl.pdf%23page%3D49&amp;token=Y1uYwcNYUkKNoFSWmQsWd8u2%2Figp3JjgxyR9Bu%2F4QvcdF608pofddFbTWmFLYWYyUVO6kVWTQJCMD6o9wrlkmumIukZVTqmsgUs36Z%2FH6ykGAN4vNRSNX%2FIqp66%2FTEMO&amp;TOPIC_ID=12971" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761088s018lbl.pdf#page=49</a></p></div>
<div class="block usep drugH1Div" id="F53568721"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Nononcologic uses: Treatment of granulomatosis with polyangiitis (Wegener granulomatosis) and microscopic polyangiitis in combination with glucocorticoids (Rituxan: FDA approved in ages ≥2 years and adults; Ruxience: FDA approved in adults); treatment of moderately- to severely-active rheumatoid arthritis (in combination with methotrexate) in patients with inadequate response to one or more tumor necrosis factor antagonists (Rituxan: FDA approved in adults); treatment of moderate to severe pemphigus vulgaris (Rituxan: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Oncologic uses: Treatment of previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL) in combination with chemotherapy (FDA approved in pediatric patients ≥6 months of age). Treatment of CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) (including relapsed or refractory, low-grade or follicular B-cell NHL [as a single agent]; follicular B-cell NHL, previously untreated [in combination with first-line chemotherapy, and as single-agent maintenance therapy if response to first-line rituximab with chemotherapy]; nonprogressing, low-grade B-cell NHL [as a single agent after first-line CVP treatment]; diffuse large B-cell NHL, previously untreated [in combination with CHOP chemotherapy or other anthracycline-based regimen]) and treatment of CD20-positive chronic lymphocytic leukemia (in combination with cyclophosphamide and fludarabine) (Rituxan, Ruxience, Truxima: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used for the treatment of systemic autoimmune disorders (eg, autoimmune hemolytic anemia); refractory systemic lupus erythematosus; steroid-refractory chronic graft-versus-host disease; refractory nephrotic syndrome; chronic immune thrombocytopenia; posttransplant lymphoproliferative disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Ruxience (rituximab-pvvr) and Truxima (rituximab-abbs), are approved as biosimilar agents; market availability unknown (see <b>Product Availability</b>). Approved ages and uses may vary (consult product labeling).</p></div>
<div class="block mst drugH1Div" id="F218877"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Rituxan may be confused with Remicade, Rituxan Hycela</p>
<p style="text-indent:-2em;margin-left:4em;">RiTUXimab may be confused with bevacizumab, brentuximab vedotin, dinutuximab, inFLIXimab, obinutuzumab, ofatumumab, polatuzumab vedotin, ramucirumab, rituximab and hyaluronidase, ruxolitinib, siltuximab, ustekinumab</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Rituximab is for intravenous (IV) administration only. Do not substitute rituximab and hyaluronidase (SubQ) for rituximab (IV). Use caution during product selection, preparation, and administration.</p>
<p style="text-indent:-2em;margin-left:4em;">The rituximab dose for rheumatoid arthritis is a flat dose (1,000 mg) and is not based on body surface area (BSA). Follow-up dosing for granulomatosis with polyangiitis and microscopic polyangiitis are flat doses and not based on BSA.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300009"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2197621"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of anti-CD20 B-cell depleting therapy is reduced. Anti-CD20 B-Cell Depleting Therapies may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belimumab: May enhance the immunosuppressive effect of RiTUXimab.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Biologic Disease-Modifying Antirheumatic Drugs (DMARDs): May enhance the immunosuppressive effect of other Biologic Disease-Modifying Antirheumatic Drugs (DMARDs).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Administer COVID-19 vaccine 2 to 4 weeks prior to the next scheduled dose of anti-CD20 therapy, if used chronically for the treatment of autoimmune disease. Revaccinate 6 months after completion of anti-CD20 therapy if used over a limited period.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines 2 weeks prior to starting anti-CD20 B-cell depleting therapies. Vaccination of patients treated with these agents in the past 6 months is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53464448"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation in patients who may become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">The manufacturer recommends patients who may become pregnant use effective contraception during therapy and for 12 months following the last rituximab dose.</p>
<p style="text-indent:0em;margin-top:2em;">Based on limited data, use of rituximab may be continued through conception in patients with rheumatic and musculoskeletal diseases who are planning a pregnancy and not able to use alternative therapies; use should be discontinued once pregnancy is confirmed. Conception should be planned during a period of quiescent/low disease activity (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Rituximab has been evaluated off-label for neuromyelitis optica spectrum disorder (NMOSD). Use of rituximab prior to pregnancy may prevent pregnancy-related attacks (Borisow 2018; Kim 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Based on limited data, use of rituximab may be continued in patients with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F218831"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Rituximab crosses the placenta and can be detected in the newborn.</p>
<p style="text-indent:0em;">Rituximab is a humanized monoclonal antibody (IgG1). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009). In one infant born at 41 weeks' gestation, in utero exposure occurred from week 16 to 37; rituximab concentrations were higher in the neonate at birth (32,095 ng/mL) than the mother (9,750 ng/mL) and still measurable at 18 weeks of age (700 ng/mL infant; 500 ng/mL mother) (Friedrichs 2006).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of rituximab during pregnancy are available (Chakravarty 2011; Das 2018; De Cock 2017; Dernoncourt 2023; Ghalandari 2022; Perrotta 2021). Although reassuring, available safety data are limited (ACOG 2019). B-cell lymphocytopenia generally lasting &lt;6 months may occur following in utero exposure. Infants and newborns exposed to rituximab during pregnancy should be monitored for infection.</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach. Based on limited data, if pregnancy occurs during rituximab treatment, rituximab should ideally be withheld. However, if postponing rituximab would significantly compromise maternal outcomes in patients diagnosed with B-cell lymphoma during pregnancy, rituximab use is not discouraged (ESMO [Peccatori 2013]). An international consensus panel has published guidelines for hematologic malignancies during pregnancy. In patients with aggressive lymphomas, rituximab (as a component of the R-CHOP chemotherapy regimen) may be administered in the second and third trimesters, however, it should be avoided within 3 weeks of anticipated delivery (Lishner 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Although approved for the treatment of rheumatoid arthritis, based on available data, rituximab should be discontinued once pregnancy is detected in patients treated for rheumatic and musculoskeletal diseases; treatment during pregnancy should only be considered for pregnant patients with life- or organ-threatening disease (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Rituximab is used off-label for the treatment of primary immune thrombocytopenia (ITP). Although data specific to pregnancy are limited, use can be considered in pregnant patients with very severe ITP. Monitor for perinatal and neonatal immunosuppression and subsequent infection (Donohoe 2019; Provan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Rituximab has been evaluated off-label for neurological indications such as multiple sclerosis (Ciplea 2020; Das 2018; Smith 2020) and neuromyelitis optica spectrum disorder (NMOSD). Maternal NMOSD may be associated with adverse pregnancy outcomes, including miscarriage and preeclampsia. Data related to the treatment of NMOSD during pregnancy are limited; however, use of rituximab prior to pregnancy may prevent pregnancy-related attacks (Borisow 2018; Chang 2020; Kim 2020; Miranda-Acuña 2019; Munger 2020; Seyed Ahadi 2021; Zhu 2020).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (1-877-635-4499).</p></div>
<div class="block mopp drugH1Div" id="F53568720"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential and platelets (pediatric and adult pediatric with lymphoid malignancies: baseline, prior to each treatment course, at weekly to monthly intervals and more frequently if cytopenias develop; pediatric and adult patients with granulomatosis with polyangiitis and microscopic polyangiitis: at 2- to 4-month intervals; in adult patients with rheumatoid arthritis: at 2- to 4-month intervals); continue to monitor for cytopenias after the final dose and until resolution, electrolytes (in patients at risk for tumor lysis syndrome [TLS]), renal function (in patients at risk for TLS), fluid/hydration status balance; blood pressure, vital signs.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for infusion reactions; signs of active hepatitis B infection (during and for up to 12 months after therapy completion); cardiac monitoring during and after infusion (in rheumatoid arthritis patients and in patients with preexisting cardiac disease or if arrhythmias develop during or after subsequent infusions); monitor for signs/symptoms of bowel obstruction/perforation (abdominal pain, vomiting); signs or symptoms of progressive multifocal leukoencephalopathy (PML) (focal neurologic deficits, which may present as hemiparesis, visual field deficits, cognitive impairment, aphasia, ataxia, and/or cranial nerve deficits); if PML is suspected, obtain brain MRI scan and lumbar puncture; signs/symptoms of TLS and/or mucocutaneous skin reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">Screen all patients for hepatitis B virus (HBV) infection prior to therapy initiation (eg, hepatitis B surface antigen [HBsAg] and hepatitis B core antibody [anti-HBc] measurements). In addition, carriers and patients with evidence of current infection or recovery from prior hepatitis B infection should be monitored closely for clinical and laboratory signs of HBV reactivation and/or infection during therapy and for up to 2 years following completion of treatment. HBV screening recommendations from adult experience (Hwang 2015): Screen for HBV infection with HBsAg and anti-HBc tests prior to treatment initiation; either a total anti-HBc (with both IgG and IgM) or anti-HBc IgG test should be used to screen for chronic or resolved HBV infection (do not use anti-HBc IgM as it may only confirm acute HBV infection). HBsAg negative/anti-HBc positive patients should be monitored for HBV reactivation with HBV DNA and ALT testing approximately every 3 months during treatment.</p></div>
<div class="block pha drugH1Div" id="F218811"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes. CD20 regulates cell cycle initiation; and, possibly, functions as a calcium channel. Rituximab binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity. B-cells are believed to play a role in the development and progression of rheumatoid arthritis. Signs and symptoms of rheumatoid arthritis are reduced by targeting B-cells and the progression of structural damage is delayed.</p></div>
<div class="block phk drugH1Div" id="F218828"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset:</p>
<p style="text-indent:-2em;margin-left:4em;">Immune thrombocytopenia: Initial response: 7 to 56 days; Peak response: 14 to 180 days (ASH [Neunert 2011]).</p>
<p style="text-indent:-2em;margin-left:4em;">Non-Hodgkin lymphomas: B-cell depletion: Within 3 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Rheumatoid arthritis: B-cell depletion: Within 2 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Non-Hodgkin lymphomas: Detectable in serum 3 to 6 months after completion of treatment; B-cell depletion is sustained for up to 6 to 9 months and B-cell recovery begins ~6 months following completion of treatment; median B-cell levels return to normal by 12 months following completion of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Rheumatoid arthritis: B-cell depletion persists for at least 6 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Pemphigus vulgaris: Median: 3.49 L (range: 2.48 to 5.22 L).</p>
<p style="text-indent:-2em;margin-left:4em;">Rheumatoid arthritis: 3.1 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Granulomatosis with polyangiitis/microscopic polyangiitis:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years of age and Adolescents ≤17 years of age: Median: 2.28 L (range: 1.43 to 3.17 L).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Median: 3.12 L (range: 2.42 to 3.91 L).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic lymphocytic leukemia: Median terminal half-life: 32 days (range: 14 to 62 days).</p>
<p style="text-indent:-2em;margin-left:4em;">Non-Hodgkin lymphomas: Median terminal half-life: 22 days (range: 6 to 52 days).</p>
<p style="text-indent:-2em;margin-left:4em;">Pemphigus vulgaris: Median terminal half-life: First cycle (1,000 mg on days 1, 15): 21.1 days (range: 9.3 to 36.2 days); second cycle (1,000 mg on days 168, 182): 26.2 days (range: 16.4 to 42.8 days).</p>
<p style="text-indent:-2em;margin-left:4em;">Rheumatoid arthritis: Mean terminal half-life: 18 days (range: 5 to 78 days).</p>
<p style="text-indent:-2em;margin-left:4em;">Granulomatosis with polyangiitis/microscopic polyangiitis:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years of age and Adolescents ≤17 years of age: Median terminal half-life: 22 days (range: 11 to 42 days).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Median terminal half-life: 25 days (range: 11 to 52 days).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance:</p>
<p style="text-indent:-2em;margin-left:4em;">Pemphigus vulgaris: Median: First cycle (1,000 mg on days 1, 15): 0.3 L/day (range: 0.16 to 1.51 L/day); second cycle (1,000 mg on days 168, 182): 0.24 L/day (range: 0.13 to 0.45 L/day).</p>
<p style="text-indent:-2em;margin-left:4em;">Rheumatoid arthritis: 0.335 L/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Granulomatosis with polyangiitis/microscopic polyangiitis:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents ≤17 years of age: Median: 0.222 L/day (range: 0.0996 to 0.381 L/day).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Median: 0.279 L/day (range: 0.133 to 0.653 L/day).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F218833"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Novex | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Ritemvia | Rixathon | Riximyo | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Riximyo | Truxima</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Rixathon | Truxima</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Riximyo | Ruxience | Truxima | Vivaxxia</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Truxima</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Mabthera</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Reditux</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Han li kang | Mabthera</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acellbia | Iximab | Maball | Mabthera | Ritoxen | Rituxan | Rixathon | Ruxience | Rytuzeq | Truxima</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Blitzima | Mabthera | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Usmal</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Reditux | Truxima</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Ruxience</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Maball | Mabthera</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Ritemvia | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Truxima</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Rixathon</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Blitzima | Mabthera | Ritemvia | Rituzena | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rituxikal | Rituxsanbe</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Riximyo | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Mabthera</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Emtux | Enfiera | Maball | Mabtas | Mabtas t | Rituxipca | Rituxirel | X mab | Zestmab</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Tromax</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Rituxan</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Intamab | Mabthera | Rilast | Rituxirel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Truxima</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Ruxience</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Truxima</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Zelva</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Arasamila | Blitzima | Kikuzubam | Mabthera | Rigetuxer | Ruxience</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Truxima</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Riximyo | Truxima</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Reditux | Rilast | Rixathon | Truxima | Zaytux</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Mabthera</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Tuximab</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Blitzima | Mabthera | Riximyo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Rituxan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Blitzima | Mabthera | Rixathon | Riximyo | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rituximab bioeticos | Tidecron</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Truxima</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Rixathon</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Acelbia | Acellbia | Mabthera | Reddytux</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Truxima</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Ritemvia | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon | Truxima</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Blitzima | Mabthera | Rixathon</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Blitzima | Mabthera | Rixathon | Riximyo | Ruxience</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Redditux | Rixathon | Truxima</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Redditux</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Redditux | Truxima</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Rixathon</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Reditux | Rituxim | Rixathon | Ruxience | Truxima</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Mabthera</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Mabthera | Novex | Rixathon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Blitzima | Mabthera | Redditux | Rixathon</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Mabthera</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24215035">
<a name="24215035"></a>Advani RH, Hoppe RT. How I treat nodular lymphocyte predominant Hodgkin lymphoma. <i>Blood</i>. 2013;122(26):4182-4188. doi:10.1182/blood-2013-07-453241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24215035/pubmed" id="24215035" target="_blank">24215035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24516013">
<a name="24516013"></a>Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. <i>J Clin Oncol</i>. 2014;32(9):912-918. doi:10.1200/JCO.2013.53.2069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24516013/pubmed" id="24516013" target="_blank">24516013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17065638">
<a name="17065638"></a>Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. <i>N Engl J Med</i>. 2006;355(17):1772-1779. doi:10.1056/NEJMoa062930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17065638/pubmed" id="17065638" target="_blank">17065638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alhamad.1">
<a name="Alhamad.1"></a>Alhamad T, Kukla A, Stratta RJ. Pancreas-kidney transplantation in diabetes mellitus: pancreas allograft rejection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed May 14, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913201">
<a name="30913201"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 776: Immune modulating therapies in pregnancy and lactation. <i>Obstet Gynecol</i>. 2019;133(4):e287-e295. doi:10.1097/AOG.0000000000003176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30913201/pubmed" id="30913201" target="_blank">30913201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17200219">
<a name="17200219"></a>Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. <i>Ann Intern Med</i>. 2007;146(1):25-33. doi:10.7326/0003-4819-146-1-200701020-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17200219/pubmed" id="17200219" target="_blank">17200219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22612239">
<a name="22612239"></a>Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. <i>Br J Haematol</i>. 2012;158(3):386-398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22612239/pubmed" id="22612239" target="_blank">22612239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14562003">
<a name="14562003"></a>Avivi I, Robinson S, Goldstone A. Clinical Use of Rituximab in Haematological Malignancies. <i>Br J Cancer</i>. 2003;89(8):1389-1394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/14562003/pubmed" id="14562003" target="_blank">14562003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31339826">
<a name="31339826"></a>Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. <i>J Clin Oncol</i>. 2019;37(31):2815-2824. doi:10.1200/JCO.19.01073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31339826/pubmed" id="31339826" target="_blank">31339826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34480762">
<a name="34480762"></a>Baradaran H, Dashti-Khavidaki S, Taher M, Talebian M, Nasiri-Toosi M, Jafarian A. Antibody-mediated rejection in adult liver transplant recipients: a case series and literature review. <i>J Clin Pharmacol.</i> 2022;62(2):254-271. doi:10.1002/jcph.1963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/34480762/pubmed" id="34480762" target="_blank">34480762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22267606">
<a name="22267606"></a>Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. <i>Blood</i>. 2012;119(16):3691-3697. doi:10.1182/blood-2011-06-363556<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22267606/pubmed" id="22267606" target="_blank">22267606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30646343">
<a name="30646343"></a>Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. <i>JAMA Netw Open</i>. 2018;1(7):e184169. doi:10.1001/jamanetworkopen.2018.4169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30646343/pubmed" id="30646343" target="_blank">30646343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23802659">
<a name="23802659"></a>Barth MJ, Goldman S, Smith L, et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. <i>Br J Haematol</i>. 2013;162(5):678-683.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23802659/pubmed" id="23802659" target="_blank">23802659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30203666">
<a name="30203666"></a>Bath RM, Doering BE, Nailor MD, Goodlet KJ. Pharmacotherapy-induced hepatitis B reactivation among patients with prior functional cure: a systematic review.<i> Ann Pharmacother.</i> 2019;53(3):294-310. doi:10.1177/1060028018800501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30203666/pubmed" id="30203666" target="_blank">30203666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32350672">
<a name="32350672"></a>Bellinvia A, Prestipino E, Portaccio E, et al. Experience with rituximab therapy in a real-life sample of multiple sclerosis patients. <i>Neurol Sci</i>. 2020;41(10):2939-2945. doi:10.1007/s10072-020-04434-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32350672/pubmed" id="32350672" target="_blank">32350672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16352811">
<a name="16352811"></a>Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. <i>Blood</i>. 2006;107(7):2639-2642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16352811/pubmed" id="16352811" target="_blank">16352811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29992013">
<a name="29992013"></a>Billon E, Stoppa AM, Mescam L, et al. Reversible rituximab-induced rectal Kaposi's sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma. <i>Clin Sarcoma Res</i>. 2018;8:11. doi:10.1186/s13569-018-0097-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/29992013/pubmed" id="29992013" target="_blank">29992013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23981017">
<a name="23981017"></a>Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. <i>Br J Haematol</i>. 2013;163(3):393-399. doi:10.1111/bjh.12541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23981017/pubmed" id="23981017" target="_blank">23981017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20002298">
<a name="20002298"></a>Borentain P, Colson P, Coso D, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. <i>J Viral Hepat</i>. 2010;17(11):807-815. doi:10.1111/j.1365-2893.2009.01239.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20002298/pubmed" id="20002298" target="_blank">20002298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30174761">
<a name="30174761"></a>Borisow N, Hellwig K, Paul F. Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. <i>EPMA J</i>. 2018;9(3):249-256. doi:10.1007/s13167-018-0143-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30174761/pubmed" id="30174761" target="_blank">30174761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33999372">
<a name="33999372"></a>Bosshard N, Zbinden A, Eriksson KK, Förger F. Rituximab and canakinumab use during lactation: no detectable serum levels in breastfed infants. <i>Rheumatol Ther</i>. 2021;8(2):1043-1048. doi:10.1007/s40744-021-00313-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33999372/pubmed" id="33999372" target="_blank">33999372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12649096">
<a name="12649096"></a>Boye J, Elter T, Engert A. An Overview of the Current Clinical Use of the Anti-CD20 Monoclonal Antibody Rituximab. <i>Ann Oncol</i>. 2003;14(4):520-535.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/12649096/pubmed" id="12649096" target="_blank">12649096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33077513">
<a name="33077513"></a>Boyiadzis MM, Aksentijevich I, Arber DA, et al. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. <i>J Immunother Cancer</i>. 2020;8(2):e000810. doi:10.1136/jitc-2020-000810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33077513/pubmed" id="33077513" target="_blank">33077513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28339781">
<a name="28339781"></a>Bragnes Y, Boshuizen R, de Vries A, et al. Low level of rituximab in human breast milk in a patient treated during lactation. <i>Rheumatology (Oxford).</i> 2017;56(6):1047-1048. doi:10.1093/rheumatology/kex039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28339781/pubmed" id="28339781" target="_blank">28339781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i>. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12393429">
<a name="12393429"></a>Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). <i>Blood</i>. 2003;101(1):6-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/12393429/pubmed" id="12393429" target="_blank">12393429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33001543">
<a name="33001543"></a>Canzian A, Venhoff N, Urban ML, et al; French Vasculitis Study Group and the European EGPA Study Group. Use of biologics to treat relapsing and/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study. <i>Arthritis Rheumatol</i>. 2021;73(3):498-503. doi:10.1002/art.41534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33001543/pubmed" id="33001543" target="_blank">33001543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20576013">
<a name="20576013"></a>Caramazza D, Quintini G, Abbene I, et al. Relapsing or Refractory Idiopathic Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome: The Role of Rituximab. <i>Transfusion</i>. 2010;50(12):2753-2760.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20576013/pubmed" id="20576013" target="_blank">20576013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25667206">
<a name="25667206"></a>Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. <i>Ann Rheum Dis</i>. 2015;74(6):1171-1177. doi:10.1136/annrheumdis-2014-206605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/25667206/pubmed" id="25667206" target="_blank">25667206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19347724">
<a name="19347724"></a>Carson KR, Bennett CL. Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. <i>Leuk Lymphoma</i>. 2009;50(3):323-324. doi:10.1080/10428190902779257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19347724/pubmed" id="19347724" target="_blank">19347724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19264918">
<a name="19264918"></a>Carson KR, Evens AM, Richey EA, et al. Progressive Multifocal Leukoencephalopathy After Rituximab Therapy in HIV-Negative Patients: A Report of 57 Cases From the Research on Adverse Drug Events and Reports Project. <i>Blood</i>. 2009;113(20):4834-4840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19264918/pubmed" id="19264918" target="_blank">19264918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33091356">
<a name="33091356"></a>Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematol.</i> 2020;7(11):e827-e837. doi:10.1016/S2352-3026(20)30224-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33091356/pubmed" id="33091356" target="_blank">33091356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32683839">
<a name="32683839"></a>Cavalcanti E, Armentano R, Lolli I. Crohn's disease following rituximab treatment for follicular lymphoma in a patient with synchronous gastric signet ring cells carcinoma: a case report and literature review. <i>Cancer Res Treat</i>. 2020;52(4):1291-1295. doi:10.4143/crt.2020.406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32683839/pubmed" id="32683839" target="_blank">32683839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21098742">
<a name="21098742"></a>Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy Outcomes Following Maternal Exposure to Rituximab. <i>Blood</i>. 2011;117(5):1499-1506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21098742/pubmed" id="21098742" target="_blank">21098742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26655421">
<a name="26655421"></a>Chanan-Khan A, Cramer P, Demirkan F, et al; HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncol</i>. 2016;17(2):200-211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/26655421/pubmed" id="26655421" target="_blank">26655421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31353503">
<a name="31353503"></a>Chang VTW, Chang HM. Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder. <i>Neuropathol Appl Neurobiol</i>. 2020;46(3):199-218. doi:10.1111/nan.12574<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31353503/pubmed" id="31353503" target="_blank">31353503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29695500">
<a name="29695500"></a>Charles P, Terrier B, Perrodeau É, et al; French Vasculitis Study Group. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). <i>Ann Rheum Dis</i>. 2018;77(8):1143-1149. doi:10.1136/annrheumdis-2017-212878<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/29695500/pubmed" id="29695500" target="_blank">29695500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26458604">
<a name="26458604"></a>Chebib R, Ghorra C, Kattan J. Safety of rituximab in a patient with chronic renal failure and low-grade non-Hodgkin lymphoma. <i>J Cancer Res Ther</i>. 2015;11(3):646. doi:10.4103/0973-1482.148677<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/26458604/pubmed" id="26458604" target="_blank">26458604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33595833">
<a name="33595833"></a>Chessa E, Piga M, Floris A, et al. Biologics and targeted synthetic drugs can induce immune-mediated glomerular disorders in patients with rheumatic diseases: an updated systematic literature review. <i>BioDrugs</i>. 2021;35(2):175-186. doi:10.1007/s40259-021-00467-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33595833/pubmed" id="33595833" target="_blank">33595833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32109194">
<a name="32109194"></a>Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. <i>J Clin Oncol.</i> 2020;38(14):1527-1538. doi:10.1200/JCO.19.02250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32109194/pubmed" id="32109194" target="_blank">32109194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27301277">
<a name="27301277"></a>Chihara D, Kantarjian H, O'Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. <i>Br J Haematol</i>. 2016;174(5):760-766. doi:10.1111/bjh.14129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27301277/pubmed" id="27301277" target="_blank">27301277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27287854">
<a name="27287854"></a>Cholera M and Chainani-Wu N. Management of pemphigus vulgaris. <i>Adv Ther</i>. 2016;33(6):910-958.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27287854/pubmed" id="27287854" target="_blank">27287854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16254143">
<a name="16254143"></a>Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. <i>Blood.</i> 2006;107(8):3053-3057. doi:10.1182/blood-2005-01-0377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16254143/pubmed" id="16254143" target="_blank">16254143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28800262">
<a name="28800262"></a>Christou EAA, Giardino G, Worth A, Ladomenou F. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. <i>Int Rev Immunol</i>. 2017;36(6):352-359. doi:10.1080/08830185.2017.1346092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28800262/pubmed" id="28800262" target="_blank">28800262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26687612">
<a name="26687612"></a>Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. <i>Lancet Haematol</i>. 2015;2(2):e75-e81. doi:10.1016/S2352-3026(15)00003-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/26687612/pubmed" id="26687612" target="_blank">26687612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34235894">
<a name="34235894"></a>Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Rheumatol</i>. 2021;73(8):1366-1383. doi:10.1002/art.41773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/34235894/pubmed" id="34235894" target="_blank">34235894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32327455">
<a name="32327455"></a>Ciplea AI, Langer-Gould A, de Vries A, et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. <i>Neurol Neuroimmunol Neuroinflamm</i>. 2020;7(4):e723. doi:10.1212/NXI.0000000000000723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32327455/pubmed" id="32327455" target="_blank">32327455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29606320">
<a name="29606320"></a>Ciron J, Audoin B, Bourre B, et al; NOMADMUS Group, under the aegis of OFSEP, SFSEP. Recommendations for the use of rituximab in neuromyelitis optica spectrum disorders. <i>Rev Neurol (Paris)</i>. 2018;174(4):255-264. doi:10.1016/j.neurol.2017.11.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/29606320/pubmed" id="29606320" target="_blank">29606320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32590421">
<a name="32590421"></a>Clark R, Lindsey D, Whiteway S, Mikita C, Lieuw K. Dysfunctional immune system reconstitution after rituximab exposure in utero. <i>J Pediatr Hematol Oncol</i>. Published online June 23, 2020. doi:10.1097/MPH.0000000000001871<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32590421/pubmed" id="32590421" target="_blank">32590421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16947627">
<a name="16947627"></a>Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. <i>Arthritis Rheum</i>. 2006;54(9):2793-2806. doi:10.1002/art.22025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16947627/pubmed" id="16947627" target="_blank">16947627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16155024">
<a name="16155024"></a>Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. <i>J Clin Oncol</i>. 2005;23(26):6387-6393. doi:10.1200/JCO.2005.05.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16155024/pubmed" id="16155024" target="_blank">16155024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9731049">
<a name="9731049"></a>Coiffier B, Haioun C, Ketterer N, et al. Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study. <i>Blood</i>. 1998;92(6):1927-1932.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/9731049/pubmed" id="9731049" target="_blank">9731049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11807147">
<a name="11807147"></a>Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. <i>N Engl J Med</i>. 2002;346(4):235-242. doi:10.1056/NEJMoa011795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/11807147/pubmed" id="11807147" target="_blank">11807147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25838326">
<a name="25838326"></a>Colvin MM, Cook JL, Chang P, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young; et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;131(18):1608-1639. doi:10.1161/CIR.0000000000000093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/25838326/pubmed" id="25838326" target="_blank">25838326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19588139">
<a name="19588139"></a>Cornejo A, Bohnenblust M, Harris C, Abrahamian GA. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation. <i>Cancer Chemother Pharmacol</i>. 2009;64(4):857-860. doi:10.1007/s00280-009-1062-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19588139/pubmed" id="19588139" target="_blank">19588139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16551963">
<a name="16551963"></a>Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. <i>Blood</i>. 2006;108(2):756-762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16551963/pubmed" id="16551963" target="_blank">16551963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27352623">
<a name="27352623"></a>Dahan K, Debiec H, Plaisier E, et al; GEMRITUX Study Group. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. <i>J Am Soc Nephrol</i>. 2017;28(1):348-358. doi:10.1681/ASN.2016040449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27352623/pubmed" id="27352623" target="_blank">27352623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27668357">
<a name="27668357"></a>Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. <i>JAMA Neurol</i>. 2016;73(11):1342-1348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27668357/pubmed" id="27668357" target="_blank">27668357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29564373">
<a name="29564373"></a>Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. <i>Neurol Neuroimmunol Neuroinflamm.</i> 2018;5(3):e453. doi:10.1212/NXI.0000000000000453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/29564373/pubmed" id="29564373" target="_blank">29564373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28137762">
<a name="28137762"></a>De Cock D, Birmingham L, Watson KD, et al; BSRBR Control Centre Consortium, Symmons DP, Hyrich KL. Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. <i>Rheumatology (Oxford).</i> 2017;56(4):661-663. doi:10.1093/rheumatology/kew493<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28137762/pubmed" id="28137762" target="_blank">28137762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26518919">
<a name="26518919"></a>De Sousa-Amorim E, Revuelta I, Blasco M, et al. Desensitization before living donor kidney transplantation in highly HLA-sensitized patients: a single-center study. <i>Transplant Proc.</i> 2015;47(8):2332-2335. doi:10.1016/j.transproceed.2015.09.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/26518919/pubmed" id="26518919" target="_blank">26518919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22147661">
<a name="22147661"></a>De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. <i>Arthritis Rheum</i>. 2012;64(3):843-853. doi:10.1002/art.34331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22147661/pubmed" id="22147661" target="_blank">22147661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DeVriese.1">
<a name="DeVriese.1"></a>De Vriese AS, Wetzels JFM, Cattran DC. Membranous nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed July 6, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24580771">
<a name="24580771"></a>Del Bello A, Congy-Jolivet N, Muscari F, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. <i>Am J Transplant</i>. 2014;14(4):867-875. doi:10.1111/ajt.12651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24580771/pubmed" id="24580771" target="_blank">24580771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19667947">
<a name="19667947"></a>Dello Strologo L, Guzzo I, Laurenzi C, et al. Use of Rituximab in Focal Glomerulosclerosis Relapses After Renal Transplantation. <i>Transplantation</i>. 2009;88(3):417-420.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19667947/pubmed" id="19667947" target="_blank">19667947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36401769">
<a name="36401769"></a>Dernoncourt A, Liabeuf S, Bennis Y, et al. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization Pharmacovigilance Database (VigiBase<sup>®</sup>). <i>BioDrugs</i>. 2023;37(1):73-87. doi:10.1007/s40259-022-00564-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/36401769/pubmed" id="36401769" target="_blank">36401769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DHHS.1">
<a name="DHHS.1"></a>DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22032879">
<a name="22032879"></a>Díaz-Largares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. <i>Autoimmun Rev</i>. 2012;11(5):357-364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22032879/pubmed" id="22032879" target="_blank">22032879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22218276">
<a name="22218276"></a>Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. <i>Neurology</i>. 2012;78(3):189-193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22218276/pubmed" id="22218276" target="_blank">22218276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17577016">
<a name="17577016"></a>Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. <i>J Clin Oncol</i>. 2007;25(22):3344-3349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17577016/pubmed" id="17577016" target="_blank">17577016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24004667">
<a name="24004667"></a>Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). <i>Blood</i>. 2013;122(19):3276-3282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24004667/pubmed" id="24004667" target="_blank">24004667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15735132">
<a name="15735132"></a>Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and Management of Waldenström's Macroglobulinemia. <i>J Clin Oncol</i>. 2005;23(7):1564-1577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15735132/pubmed" id="15735132" target="_blank">15735132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29856685">
<a name="29856685"></a>Dimopoulos MA, Tedeschi A, Trotman J, et al; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. <i>N Engl J Med.</i> 2018;378(25):2399-2410. doi:10.1056/NEJMoa1802917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/29856685/pubmed" id="29856685" target="_blank">29856685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Djamali.1">
<a name="Djamali.1"></a>Djamali A, Brennan DC. Kidney transplantation in adults: prevention and treatment of antibody-mediated rejection of the renal allograft. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31853261">
<a name="31853261"></a>Donohoe F, Higgins M, Higgins S, McAuliffe F, Murphy K. Rituximab - a novel therapy for severe ITP in pregnancy: a case report. <i>Obstet Med</i>. 2019;12(4):196-198. doi:10.1177/1753495X18778489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31853261/pubmed" id="31853261" target="_blank">31853261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28444729">
<a name="28444729"></a>Ducassou S, Leverger G, Fernandes H, et al. Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. <i>Br J Haematol</i>. 2017;177(5):751-758.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28444729/pubmed" id="28444729" target="_blank">28444729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28915275">
<a name="28915275"></a>Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. <i>PLoS One</i>. 2017;12(9):e0183844. doi:10.1371/journal.pone.0183844<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28915275/pubmed" id="28915275" target="_blank">28915275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15201414">
<a name="15201414"></a>Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. <i>N Engl J Med</i>. 2004;350(25):2572-2581. doi:10.1056/NEJMoa032534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15201414/pubmed" id="15201414" target="_blank">15201414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216274">
<a name="27216274"></a>Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. <i>Lancet Oncol.</i> 2016;17(7):928-942.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27216274/pubmed" id="27216274" target="_blank">27216274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12586628">
<a name="12586628"></a>Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. <i>Blood. </i>2003;101(11):4285-4289. doi:10.1182/blood-2002-08-2644<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/12586628/pubmed" id="12586628" target="_blank">12586628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16908351">
<a name="16908351"></a>El Tal AK, Posner MR, Spigelman Z, et al. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. <i>J Am Acad Dermatol</i>. 2006;55(3):449-459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16908351/pubmed" id="16908351" target="_blank">16908351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23016878">
<a name="23016878"></a>Else M, Marín-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. <i>Br J Haematol</i>. 2012;159(3):322-328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23016878/pubmed" id="23016878" target="_blank">23016878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15365145">
<a name="15365145"></a>Enting RH, Demopoulos A, DeAngelis LM, et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. <i>Neurology</i>. 2004;63(5):901-903.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15365145/pubmed" id="15365145" target="_blank">15365145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21115603">
<a name="21115603"></a>Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. <i>Ann Oncol</i>. 2011;22(5):1170-1180. doi:10.1093/annonc/mdq583<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21115603/pubmed" id="21115603" target="_blank">21115603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17496547">
<a name="17496547"></a>Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. <i>Transplantation</i>. 2007;83(9):1277-1280. doi:10.1097/01.tp.0000261113.30757.d1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17496547/pubmed" id="17496547" target="_blank">17496547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15933059">
<a name="15933059"></a>Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. <i>Blood</i>. 2005;106(6):1932-1937. doi:10.1182/blood-2005-03-0848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15933059/pubmed" id="15933059" target="_blank">15933059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Falk.1">
<a name="Falk.1"></a>Falk RJ, Dall’Era M, Allel GB. Lupus nephritis: treatment of focal of diffuse lupus nephritis resistant to initial therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32220834">
<a name="32220834"></a>Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Ann Rheum Dis.</i> 2020;79(6):713-723. doi:10.1136/annrheumdis-2020-216924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32220834/pubmed" id="32220834" target="_blank">32220834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31462584">
<a name="31462584"></a>Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31462584/pubmed" id="31462584" target="_blank">31462584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17988304">
<a name="17988304"></a>Feldmann G, Nattermann J, Gerhardt T, Nähle CP, Spengler U, Woitas R. Partial remission of a newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP. <i>Int J Lab Hematol</i>. 2007;29(6):469-473. doi:10.1111/j.1365-2257.2006.00879.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17988304/pubmed" id="17988304" target="_blank">17988304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20705965">
<a name="20705965"></a>Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. <i>Clin J Am Soc Nephrol</i>. 2010;5(12):2188-2198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20705965/pubmed" id="20705965" target="_blank">20705965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31269364">
<a name="31269364"></a>Fervenza FC, Appel GB, Barbour SJ, et al; MENTOR Investigators. Rituximab or cyclosporine in the treatment of membranous nephropathy. <i>N Engl J Med</i>. 2019;381(1):36-46. doi:10.1056/NEJMoa1814427<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31269364/pubmed" id="31269364" target="_blank">31269364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17943078">
<a name="17943078"></a>Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. <i>Kidney Int</i>. 2008;73(1):117-125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17943078/pubmed" id="17943078" target="_blank">17943078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fervenza.1">
<a name="Fervenza.1"></a>Fervenza FC, Leise MD, Roccatello D. Mixed cryoglobulinemia syndrome: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed May 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21844497">
<a name="21844497"></a>Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. <i>J Clin Oncol</i>. 2011;29(26):3559-3566. doi:10.1200/JCO.2010.33.8061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21844497/pubmed" id="21844497" target="_blank">21844497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30293439">
<a name="30293439"></a>Fogueri U, Cheungapasitporn W, Bourne D, Fervenza FC, Joy MS. Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy. <i>Ann Pharmacother</i>. 2019;53(4):357-363. doi:10.1177/1060028018803587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30293439/pubmed" id="30293439" target="_blank">30293439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013416">
<a name="33013416"></a>Fouda GE, Bavbek S. Rituximab hypersensitivity: from clinical presentation to management. <i>Front Pharmacol</i>. 2020;11:572863. doi:10.3389/fphar.2020.572863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33013416/pubmed" id="33013416" target="_blank">33013416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16963391">
<a name="16963391"></a>Friedrichs B, Tiemann M, Salwender H, et al. The effects of rituximab treatment during pregnancy on a neonate. <i>Haematologica</i>. 2006;91(10):1426-1427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16963391/pubmed" id="16963391" target="_blank">16963391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20049616">
<a name="20049616"></a>Fujinaga S, Hirano D, Nishizaki N, et al. Single Infusion of Rituximab for Persistent Steroid-Dependent Minimal-Change Nephrotic Syndrome After Long-Term Cyclosporine. <i>Pediatr Nephrol</i>. 2010;25(3):539-544.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20049616/pubmed" id="20049616" target="_blank">20049616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24450857">
<a name="24450857"></a>Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. <i>N Engl J Med</i>. 2014;370(11):997-1007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24450857/pubmed" id="24450857" target="_blank">24450857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17233819">
<a name="17233819"></a>García-Suárez J, Bañas H, Arribas I, De Miguel D, Pascual T, Burgaleta C. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. <i>Br J Haematol</i>. 2007;136(2):276-285.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17233819/pubmed" id="17233819" target="_blank">17233819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16315252">
<a name="16315252"></a>Garcia-Suarez J, de Miguel D, Krsnik I, et al. Changes in the Natural History of Progressive Multifocal Leukoencephalopathy in HIV-Negative Lymphoproliferative Disorders: Impact of Novel Therapies. <i>Am J Hematol</i>. 2005;80(4):271-281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16315252/pubmed" id="16315252" target="_blank">16315252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30044684">
<a name="30044684"></a>Geller S, Dickson MA, Busam KJ, Myskowski PL. Kaposi's sarcoma after autologous stem-cell transplantation and rituximab treatment. <i>J Oncol Pract</i>. 2018;14(9):565-568. doi:10.1200/JOP.18.00246<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30044684/pubmed" id="30044684" target="_blank">30044684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30406172">
<a name="30406172"></a>Georgakopoulos JR, Rohekar G, Lovegrove FE. A case of rituximab-induced pyoderma gangrenosum. <i>JAAD Case Rep</i>. 2018;4(10):979-981. doi:10.1016/j.jdcr.2018.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30406172/pubmed" id="30406172" target="_blank">30406172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-George.1">
<a name="George.1"></a>George JN, Cuker A. Acquired TTP: management following recovery from an acute episode and during remission. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed July 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35894810">
<a name="35894810"></a>Ghalandari N, Crijns HJMJ, Bergman JEH, Dolhain RJEM, van Puijenbroek EP, Hazes JMW. Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: a retrospective comparative study in EudraVigilance. <i>Br J Clin Pharmacol</i>. 2022;88(12):5378-5388. doi:10.1111/bcp.15471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/35894810/pubmed" id="35894810" target="_blank">35894810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14976046">
<a name="14976046"></a>Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. <i>Blood</i>. 2004;103(12):4416-4423. doi:10.1182/blood-2003-10-3411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/14976046/pubmed" id="14976046" target="_blank">14976046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20142586">
<a name="20142586"></a>Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. <i>J Clin Oncol</i>. 2010;28(8):1422-1428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20142586/pubmed" id="20142586" target="_blank">20142586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20660832">
<a name="20660832"></a>Gisselbrecht C, Glass B, Mounier N, et al. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. <i>J Clin Oncol</i>. 2010;28(27):4184-4190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20660832/pubmed" id="20660832" target="_blank">20660832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29082519">
<a name="29082519"></a>Giulino-Roth L, O'Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. <i>Br J Haematol</i>. 2017;179(5):739-747.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/29082519/pubmed" id="29082519" target="_blank">29082519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21981575">
<a name="21981575"></a>Gobert D, Bussel JB, Cunningham-Rundles C, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. <i>Br J Haematol</i>. 2011;155(4):498-508. doi:10.1111/j.1365-2141.2011.08880.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21981575/pubmed" id="21981575" target="_blank">21981575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18463354">
<a name="18463354"></a>Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. <i>Blood</i>. 2008;112(4):999-1004. doi:10.1182/blood-2008-01-131029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/18463354/pubmed" id="18463354" target="_blank">18463354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11830505">
<a name="11830505"></a>Goldberg SL, Pecora AL, Alter RS, et al. Unusual Viral Infections (Progressive Multifocal Leukoencephalopathy and Cytomegalovirus Disease) After High-Dose Chemotherapy With Autologous Blood Stem Cell Rescue and Peritransplantation Rituximab. <i>Blood</i>. 2002;99(4):1486-1488.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/11830505/pubmed" id="11830505" target="_blank">11830505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22940833">
<a name="22940833"></a>Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. <i>Leukemia</i>. 2013;27(5):1174-1177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22940833/pubmed" id="22940833" target="_blank">22940833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35718887">
<a name="35718887"></a>Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(9):1399-1408. doi:10.1002/acr.24893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/35718887/pubmed" id="35718887" target="_blank">35718887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15550531">
<a name="15550531"></a>Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and Short Term Efficacy of Rituximab in 43 Patients With Systemic Autoimmune Diseases. <i>Ann Rheum Dis</i>. 2005;64(6):913-920.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15550531/pubmed" id="15550531" target="_blank">15550531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23502429">
<a name="23502429"></a>Gregory G, Arumugaswamy A, Leung T, et al. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. <i>Neuro Oncol</i>. 2013;15(8):1068-1073.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23502429/pubmed" id="23502429" target="_blank">23502429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18816698">
<a name="18816698"></a>Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Pediatr Blood Cancer</i>. 2009;52(2):177-181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/18816698/pubmed" id="18816698" target="_blank">18816698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14686699">
<a name="14686699"></a>Grillo-Lopez AJ. Rituximab (Rituxan/MabThera): The First Decade (1993-2003). <i>Expert Rev Anticancer Ther</i>. 2003;3(6):767-779.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/14686699/pubmed" id="14686699" target="_blank">14686699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18465150">
<a name="18465150"></a>Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab Treatment for Severe Steroid- or Cyclosporine-Dependent Nephrotic Syndrome: A Multicentric Series of 22 Cases. <i>Pediatr Nephrol</i>. 2008;23(8):1269-1279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/18465150/pubmed" id="18465150" target="_blank">18465150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25372085">
<a name="25372085"></a>Guillevin L, Pagnoux C, Karras A, et al; French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. <i>N Engl J Med</i>. 2014;371(19):1771-1780. doi:10.1056/NEJMoa1404231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/25372085/pubmed" id="25372085" target="_blank">25372085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20798255">
<a name="20798255"></a>Gulati A, Sinha A, Jordan SC, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. <i>Clin J Am Soc Nephrol</i>. 2010;5(12):2207-2212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20798255/pubmed" id="20798255" target="_blank">20798255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hachem.1">
<a name="Hachem.1"></a>Hachem RR. Evaluation and treatment of antibody-mediated lung transplant rejection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed January 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20558084">
<a name="20558084"></a>Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. <i>J Heart Lung Transplant</i>. 2010;29(9):973-980. doi:10.1016/j.healun.2010.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20558084/pubmed" id="20558084" target="_blank">20558084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22556106">
<a name="22556106"></a>Hahn BH, McMahon MA, Wilkinson A, et al; American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(6):797-808. doi:10.1002/acr.21664<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22556106/pubmed" id="22556106" target="_blank">22556106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24500264">
<a name="24500264"></a>Heelan K, Al-Mohammedi F, Smith MJ, et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. <i>JAMA Dermatol</i>. 2014;150(7):703-708. doi:10.1001/jamadermatol.2013.6739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24500264/pubmed" id="24500264" target="_blank">24500264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16265687">
<a name="16265687"></a>Higashida J, Wun T, Schmidt S, et al. Safety and Efficacy of Rituximab in Patients With Rheumatoid Arthritis Refractory to Disease Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor-Alpha Treatment. <i>J Rheumatol</i>. 2005;32(11):2109-2115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16265687/pubmed" id="16265687" target="_blank">16265687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25359988">
<a name="25359988"></a>Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. <i>Blood</i>. 2014;124(26):3870-3879.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/25359988/pubmed" id="25359988" target="_blank">25359988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24928128">
<a name="24928128"></a>Holdhoff M, Ambady P, Abdelaziz A, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. <i>Neurology</i>. 2014;83(3):235-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24928128/pubmed" id="24928128" target="_blank">24928128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update.<i> J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30892921">
<a name="30892921"></a>Hwang JP, Huang D, Vierling JM, et al. Cost-effectiveness analysis of hepatitis B virus screening and management in patients with hematologic or solid malignancies anticipating immunosuppressive cancer therapy. <i>JCO Clin Cancer Inform</i>. 2019;3:1-12. doi:10.1200/CCI.18.00097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30892921/pubmed" id="30892921" target="_blank">30892921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27500219">
<a name="27500219"></a>Ide K, Tanaka Y, Sasaki Y, et al. A phased desensitization protocol with rituximab and bortezomib for highly sensitized kidney transplant candidates. <i>Transplant Direct</i>. 2015;1(5):e17. doi:10.1097/TXD.0000000000000526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27500219/pubmed" id="27500219" target="_blank">27500219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24965823">
<a name="24965823"></a>Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet</i>. 2014;384(9950):1273-1281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24965823/pubmed" id="24965823" target="_blank">24965823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women [published correction appears in <i>N Engl J Med</i> 2000;343(18):1348]. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31839434">
<a name="31839434"></a>Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. <i>Blood Rev</i>. 2020;41:100648. doi:10.1016/j.blre.2019.100648<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31839434/pubmed" id="31839434" target="_blank">31839434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26844479">
<a name="26844479"></a>Jeong JC, Jambaldorj E, Kwon HY, et al. Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation. <i>Medicine (Baltimore)</i>. 2016;95(5):e2635. doi:10.1097/MD.0000000000002635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/26844479/pubmed" id="26844479" target="_blank">26844479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30201758">
<a name="30201758"></a>Jestin M, Benhamou Y, Schelpe AS, et al; French Thrombotic Microangiopathies Reference Center. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. <i>Blood</i>. 2018;132(20):2143-2153. doi:10.1182/blood-2018-04-840090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30201758/pubmed" id="30201758" target="_blank">30201758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12410580">
<a name="12410580"></a>Jillella AP, Dainer PM, Kallab AM, Ustun C. Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. <i>Am J Hematol</i>. 2002;71(3):219-222. doi:10.1002/ajh.10213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/12410580/pubmed" id="12410580" target="_blank">12410580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12652458">
<a name="12652458"></a>Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. <i>Semin Oncol</i>. 2003;30(1)(suppl 2):3-8. doi:10.1053/sonc.2003.50025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/12652458/pubmed" id="12652458" target="_blank">12652458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32830877">
<a name="32830877"></a>Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). <i>J Eur Acad Dermatol Venereol</i>. 2020;34(9):1900-1913. doi:10.1111/jdv.16752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32830877/pubmed" id="32830877" target="_blank">32830877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28342637">
<a name="28342637"></a>Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. <i>Lancet</i>. 2017;389(10083):2031-2040. doi:10.1016/S0140-6736(17)30070-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28342637/pubmed" id="28342637" target="_blank">28342637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20647198">
<a name="20647198"></a>Jones RB, Tervaert JW, Hauser T, et al. Rituximab Versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. <i>N Engl J Med</i>. 2010;363(3):211-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20647198/pubmed" id="20647198" target="_blank">20647198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22382230">
<a name="22382230"></a>Kadikoy H, Haque W, Ahmed S, Abdellatif A. Rituximab in the treatment of refractory lupus nephritis with vasculitis. <i>Saudi J Kidney Dis Transpl</i>. 2012;23(2):334-337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22382230/pubmed" id="22382230" target="_blank">22382230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27529314">
<a name="27529314"></a>Kahwaji J, Jordan SC, Najjar R, et al. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab. <i>Transpl Int.</i> 2016;29(12):1276-1285. doi:10.1111/tri.12832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27529314/pubmed" id="27529314" target="_blank">27529314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20033219">
<a name="20033219"></a>Kaito H, Kamei K, Kikuchi E, et al. Successful Treatment of Collapsing Focal Segmental Glomerulosclerosis With a Combination of Rituximab, Steroids, and Ciclosporin. <i>Pediatr Nephrol</i>. 2010;25(5):957-959.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20033219/pubmed" id="20033219" target="_blank">20033219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23345547">
<a name="23345547"></a>Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. <i>Oncologist</i>. 2013;18(2):190-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23345547/pubmed" id="23345547" target="_blank">23345547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19610146">
<a name="19610146"></a>Kamar N, Lavayssière L, Muscari F, et al. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. <i>World J Gastroenterol.</i> 2009;15(27):3426-3430. doi:10.3748/wjg.15.3426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19610146/pubmed" id="19610146" target="_blank">19610146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19421786">
<a name="19421786"></a>Kamei K, Ito S, Nozu K, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. <i>Pediatr Nephrol</i>. 2009;24(7):1321-1328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19421786/pubmed" id="19421786" target="_blank">19421786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18589184">
<a name="18589184"></a>Kaposztas Z, Etheridge WB, Kahan BD. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus. <i>Transplant Proc</i>. 2008;40(5):1744-1746. doi:10.1016/j.transproceed.2007.11.072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/18589184/pubmed" id="18589184" target="_blank">18589184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19200217">
<a name="19200217"></a>Kaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. <i>Clin Transplant</i>. 2009;23(1):63-73. doi:10.1111/j.1399-0012.2008.00902.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19200217/pubmed" id="19200217" target="_blank">19200217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22967460">
<a name="22967460"></a>Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective. <i>Crit Care</i>. 2012;16(4):231. doi:10.1186/cc11304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22967460/pubmed" id="22967460" target="_blank">22967460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21641080">
<a name="21641080"></a>Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. <i>J Am Acad Dermatol</i>. 2011;65(3):552-558.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21641080/pubmed" id="21641080" target="_blank">21641080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30523712">
<a name="30523712"></a>Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study.<i> J Clin Oncol.</i> 2019;37(4):269-277. doi:10.1200/JCO.18.01580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30523712/pubmed" id="30523712" target="_blank">30523712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32986498">
<a name="32986498"></a>Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. <i>J Clin Oncol</i>. 2020;38(34):4042-4054. doi:10.1200/JCO.20.00948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32986498/pubmed" id="32986498" target="_blank">32986498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15767648">
<a name="15767648"></a>Keating MJ, O’Brien S, Albitar M, et al. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia. <i>J Clin Oncol</i>. 2005;23(18):4079-488.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15767648/pubmed" id="15767648" target="_blank">15767648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23235801">
<a name="23235801"></a>Ketterer N, Coiffier B, Thieblemont C, et al. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). <i>Ann Oncol</i>. 2013;24(4):1032-1037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23235801/pubmed" id="23235801" target="_blank">23235801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20191576">
<a name="20191576"></a>Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. <i>Arthritis Rheum</i>. 2010;62(6):1755-1762. doi:10.1002/art.27435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20191576/pubmed" id="20191576" target="_blank">20191576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22210556">
<a name="22210556"></a>Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. <i>Medicine (Baltimore)</i>. 2012;91(1):57-66. doi:10.1097/MD.0b013e3182431ef6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22210556/pubmed" id="22210556" target="_blank">22210556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney disease: improving global outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. <i>Kidney Inter</i>. 2012;2:139–274.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31818254">
<a name="31818254"></a>Kim DG, Lee J, Park Y, et al. Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study. <i>BMC Nephrol.</i> 2019;20(1):456. doi:10.1186/s12882-019-1625-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31818254/pubmed" id="31818254" target="_blank">31818254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19382999">
<a name="19382999"></a>Kim MJ, Kim HO, Kim HY, Park YM. Rituximab-induced vasculitis: a case report and review of the medical published work. <i>J Dermatol</i>. 2009;36(5):284-287. doi:10.1111/j.1346-8138.2009.00639.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19382999/pubmed" id="19382999" target="_blank">19382999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32320109">
<a name="32320109"></a>Kim SH, Huh SY, Jang H, et al. Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder. <i>Eur J Neurol</i>. 2020;27(8):1546-1555. doi:10.1111/ene.14274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32320109/pubmed" id="32320109" target="_blank">32320109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20663943">
<a name="20663943"></a>Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. <i>Haematologica</i>. 2010;95(11):1935-1942.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20663943/pubmed" id="20663943" target="_blank">20663943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11889454">
<a name="11889454"></a>Kollmar O, Becker S, Schilling MK, Maurer CA. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy. <i>Transplantation</i>. 2002;73(4):669-670. doi:10.1097/00007890-200202270-00038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/11889454/pubmed" id="11889454" target="_blank">11889454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31719115">
<a name="31719115"></a>Krysko KM, LaHue SC, Anderson A, et al. Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions. <i>Neurol Neuroimmunol Neuroinflamm</i>. 2019;7(1):e637. doi:10.1212/NXI.0000000000000637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31719115/pubmed" id="31719115" target="_blank">31719115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28151390">
<a name="28151390"></a>Ladogana S, Maruzzi M, Samperi P, et al. Diagnosis and management of newly diagnosed childhood autoimmune haemolytic anaemia. Recommendations from the Red Cell Study Group of the Paediatric Haemato-Oncology Italian Association. <i>Blood Transfus</i>. 2017;15(3):259-267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28151390/pubmed" id="28151390" target="_blank">28151390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leandro.1">
<a name="Leandro.1"></a>Leandro MJ. Rituximab: principles of use and adverse effects in rheumatoid arthritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed July 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20548093">
<a name="20548093"></a>Lechner K and Jäger U. How I treat autoimmune hemolytic anemias in adults. <i>Blood</i>. 2010;116(11):1831-1838.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20548093/pubmed" id="20548093" target="_blank">20548093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22410063">
<a name="22410063"></a>Lee CF, Eldeen FZ, Chan KM, et al. Bortezomib is effective to treat acute humoral rejection after liver transplantation. <i>Transplant Proc</i>. 2012;44(2):529-531. doi:10.1016/j.transproceed.2012.01.051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22410063/pubmed" id="22410063" target="_blank">22410063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19422335">
<a name="19422335"></a>Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. <i>Am J Transplant</i>. 2009;9(5):1099-1107. doi:10.1111/j.1600-6143.2009.02591.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19422335/pubmed" id="19422335" target="_blank">19422335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29042839">
<a name="29042839"></a>Legeay C, Bittencourt H, Haddad E, Spiesser-Robelet L, Thépot-Seegers V, Therrien R. A retrospective study on infusion-related reactions to rituximab in a heterogeneous pediatric population. <i>J Pediatr Pharmacol Ther</i>. 2017;22(5):369-374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/29042839/pubmed" id="29042839" target="_blank">29042839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26583612">
<a name="26583612"></a>Legeay C, Spiesser-Robelet L, Bittencourt H, Haddad E, Therrien R. Rapid infusion of rituximab in a heterogenous pediatric population: safety and feasibility. <i>J Pediatr Hematol Oncol</i>. 2016;38(1):83-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/26583612/pubmed" id="26583612" target="_blank">26583612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17522249">
<a name="17522249"></a>Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. <i>Oncologist</i>. 2007;12(5):601-609. doi:10.1634/theoncologist.12-5-601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17522249/pubmed" id="17522249" target="_blank">17522249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30897038">
<a name="30897038"></a>Leonard JP, Trneny M, Izutsu K, et al; AUGMENT Trial Investigators. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. <i>J Clin Oncol</i>. 2019;37(14):1188-1199. doi:10.1200/JCO.19.00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30897038/pubmed" id="30897038" target="_blank">30897038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33202411">
<a name="33202411"></a>Liccioli G, Simonini G, Melani F, et al. Hypersensitivity to rituximab in children. <i>Pharmacology</i>. 2021;106(5-6):341-344. doi:10.1159/000511458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33202411/pubmed" id="33202411" target="_blank">33202411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33581791">
<a name="33581791"></a>Li T, Zhang GQ, Li Y, et al. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: a meta-analysis. <i>J Clin Neurosci</i>. 2021;85:6-12. doi:10.1016/j.jocn.2020.11.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33581791/pubmed" id="33581791" target="_blank">33581791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26628463">
<a name="26628463"></a>Lishner M, Avivi I, Apperley JF, et al. Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. <i>J Clin Oncol</i>. 2016;34(5):501-508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/26628463/pubmed" id="26628463" target="_blank">26628463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32311997">
<a name="32311997"></a>Lu W, Gong S, Li J, Luo H, Wang Y. Efficacy and safety of rituximab in the treatment of membranous nephropathy: a systematic review and meta-analysis. <i>Medicine (Baltimore).</i> 2020;99(16):e19804. doi:10.1097/MD.0000000000019804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32311997/pubmed" id="32311997" target="_blank">32311997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21571768">
<a name="21571768"></a>Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC. Rituximab treatment in patients with refractory inflammatory myopathies. <i>Rheumatology (Oxford).</i> 2011;50(12):2206-2213. doi:10.1093/rheumatology/ker088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21571768/pubmed" id="21571768" target="_blank">21571768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24778295">
<a name="24778295"></a>Makatsori M, Kiani-Alikhan S, Manson AL, et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. <i>QJM</i>. 2014;107(10):821-828. doi:10.1093/qjmed/hcu094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24778295/pubmed" id="24778295" target="_blank">24778295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23124537">
<a name="23124537"></a>Malina M, Schaefer B, Waldherr R, Wühl E, Schaefer F, Schmitt CP. Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis. <i>Pediatr Nephrol</i>. 2013;28(3):511-514. doi:10.1007/s00467-012-2332-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23124537/pubmed" id="23124537" target="_blank">23124537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30302361">
<a name="30302361"></a>Maloney C, Blickenstaff N, Kugasia A, Buford LB, Hoffman MD. Vulvovaginal pyoderma gangrenosum in association with rituximab. <i>JAAD Case Rep</i>. 2018;4(9):907-909. doi:10.1016/j.jdcr.2018.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30302361/pubmed" id="30302361" target="_blank">30302361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32810220">
<a name="32810220"></a>Maloney DG, Ogura M, Fukuhara N, et al. A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy.<i> Blood Adv.</i> 2020;4(16):3886-3893. doi:10.1182/bloodadvances.2020001942<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32810220/pubmed" id="32810220" target="_blank">32810220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28140087">
<a name="28140087"></a>Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. <i>Semin Oncol</i>. 2002;29(1)(suppl 2):2-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28140087/pubmed" id="28140087" target="_blank">28140087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494430">
<a name="15494430"></a>Marcus R, Imrie K, Belch A, et al. CVP Chemotherapy Plus Rituximab Compared With CVP as First-Line Treatment for Advanced Follicular Lymphoma. <i>Blood</i>. 2005;105(4):1417-1423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15494430/pubmed" id="15494430" target="_blank">15494430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16200620">
<a name="16200620"></a>Marks SD, Patey S, Brogan PA, et al. B Lymphocyte Depletion Therapy in Children With Refractory Systemic Lupus Erythematosus. <i>Arthritis Rheum</i>. 2005;52(10):3168-3174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16200620/pubmed" id="16200620" target="_blank">16200620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15668468">
<a name="15668468"></a>Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-<i>Helicobacter pylori</i> therapy. <i>J Clin Oncol</i>. 2005;23(9):1979-1983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15668468/pubmed" id="15668468" target="_blank">15668468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27626518">
<a name="27626518"></a>Maury S, Chevret S, Thomas X, et al; for GRAALL. Rituximab in B-lineage adult acute lymphoblastic leukemia. <i>N Engl J Med</i>. 2016;375(11):1044-1053. doi:10.1056/NEJMoa1605085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27626518/pubmed" id="27626518" target="_blank">27626518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20175870">
<a name="20175870"></a>McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. <i>J Thromb Haemost</i>. 2010;8(6):1201-1208. doi:10.1111/j.1538-7836.2010.03818.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20175870/pubmed" id="20175870" target="_blank">20175870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9704735">
<a name="9704735"></a>McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. <i>J Clin Oncol</i>. 1998;16(8):2825-2833.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/9704735/pubmed" id="9704735" target="_blank">9704735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24445513">
<a name="24445513"></a>Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. <i>JAMA Neurol</i>. 2014;71(3):324-330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24445513/pubmed" id="24445513" target="_blank">24445513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22232754">
<a name="22232754"></a>Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. <i>J Clin Pharmacol</i>. 2012;52(1)(suppl):54S-62S. doi:10.1177/0091270011413894<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22232754/pubmed" id="22232754" target="_blank">22232754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19261822">
<a name="19261822"></a>Melander C, Sallée M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. <i>Clin J Am Soc Nephrol</i>. 2009;4(3):579-587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19261822/pubmed" id="19261822" target="_blank">19261822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16426331">
<a name="16426331"></a>Melcher ML, Olson JL, Baxter-Lowe LA, Stock PG, Posselt AM. Antibody-mediated rejection of a pancreas allograft. <i>Am J Transplant</i>. 2006;6(2):423-428. doi:10.1111/j.1600-6143.2005.01185.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16426331/pubmed" id="16426331" target="_blank">16426331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merkel.1">
<a name="Merkel.1"></a>Merkel PA, Kaplan AA, Falk RJ. Granulomatosis with polyangiitis and microscopic polyangiitis: induction and maintenance therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed July 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyrier.1">
<a name="Meyrier.1"></a>Meyrier A, Radhakrishnan J. Minimal change disease: treatment in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10707791">
<a name="10707791"></a>Milpied N, Vasseur B, Parquet N, et al. Humanized Anti-CD20 Monoclonal Antibody (Rituximab) in Post Transplant B-Lymphoproliferative Disorder: A Retrospective Analysis on 32 Patients. <i>Ann Oncol</i>, 2000;11(suppl 1):113-116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/10707791/pubmed" id="10707791" target="_blank">10707791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30800724">
<a name="30800724"></a>Miranda-Acuña J, Rivas-Rodríguez E, Levy M, et al. Rituximab during pregnancy in neuromyelitis optica: A case report. <i>Neurol Neuroimmunol Neuroinflamm</i>. 2019;6(2):e542. doi:10.1212/NXI.0000000000000542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30800724/pubmed" id="30800724" target="_blank">30800724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22422012">
<a name="22422012"></a>Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. <i>Arthritis Rheum</i>. 2012;64(9):3043-3051. doi:10.1002/art.34468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22422012/pubmed" id="22422012" target="_blank">22422012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15235579">
<a name="15235579"></a>Moore J, Ma D, Will R, et al. A Phase II Study of Rituximab in Rheumatoid Arthritis Patients With Recurrent Disease Following Haematopoietic Stem Cell Transplantation. <i>Bone Marrow Transplant</i>. 2004;34(3):241-247.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15235579/pubmed" id="15235579" target="_blank">15235579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20930448">
<a name="20930448"></a>Morita Y, Matsuda M, Yamaguchi T, et al. Efficacy of rituximab monotherapy for an elderly hemodialysis patient with primary cardiac lymphoma. <i>Intern Med</i>. 2010;49(19):2163-2166. doi:10.2169/internalmedicine.49.4018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20930448/pubmed" id="20930448" target="_blank">20930448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moutsopoulos.1">
<a name="Moutsopoulos.1"></a>Moutsopoulos HM, Fragoulis GE, Stone JH. Treatment and prognosis of IgG4-related disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed May 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32173005">
<a name="32173005"></a>Munger KC, Samkoff LM. Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy. <i>Mult Scler Relat Disord</i>. 2020;37:101442. doi:10.1016/j.msard.2019.101442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32173005/pubmed" id="32173005" target="_blank">32173005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30398015">
<a name="30398015"></a>Mustafa KN, Qasem U, Al-Ryalat NT, Bsisu IK. Rituximab-associated posterior reversible encephalopathy syndrome. <i>Int J Rheum Dis</i>. 2019;22(1):160-165. doi:10.1111/1756-185X.13427<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30398015/pubmed" id="30398015" target="_blank">30398015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NCT01750697.1">
<a name="NCT01750697.1"></a>NCT01750697. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. <a href="https://clinicaltrials.gov/ct2/show/NCT01750697" target="_blank">https://clinicaltrials.gov/ct2/show/NCT01750697</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Negrin.1">
<a name="Negrin.1"></a>Negrin RS, Brennan DC. Treatment and prevention of post-transplant lymphoproliferative disorders. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21325604">
<a name="21325604"></a>Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i>. 2011;117(16):4190-4207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21325604/pubmed" id="21325604" target="_blank">21325604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31794604">
<a name="31794604"></a>Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Adv.</i> 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31794604/pubmed" id="31794604" target="_blank">31794604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15951469">
<a name="15951469"></a>Ng CM, Bruno R, Combs D, et al. Population Pharmacokinetics of Rituximab (Anti-CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial. <i>J Clin Pharmacol</i>. 2005;45(7):792-801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15951469/pubmed" id="15951469" target="_blank">15951469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16541475">
<a name="16541475"></a>Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. <i>J Rheumatol</i>. 2006;33(5):1021-1026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16541475/pubmed" id="16541475" target="_blank">16541475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18097688">
<a name="18097688"></a>Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. <i>Pediatr Nephrol</i>. 2008;23(3):413-419.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/18097688/pubmed" id="18097688" target="_blank">18097688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26689650">
<a name="26689650"></a>Ochi Y, Hiramoto N, Ono Y, et al. Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis. <i>Leuk Lymphoma</i>. 2016;57(8):1945-1948. doi:10.3109/10428194.2015.1115033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/26689650/pubmed" id="26689650" target="_blank">26689650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23124935">
<a name="23124935"></a>Oddis CV, Reed AM, Aggarwal R, et al; RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. <i>Arthritis Rheum</i>. 2013;65(2):314-324. doi:10.1002/art.37754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23124935/pubmed" id="23124935" target="_blank">23124935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23348804">
<a name="23348804"></a>Olszewski AJ, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. <i>Ann Oncol</i>. 2013;24(5):1352-1359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23348804/pubmed" id="23348804" target="_blank">23348804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15693112">
<a name="15693112"></a>Panayi GS. B Cell-Directed Therapy in Rheumatoid Arthritis - Clinical Experience. <i> J Rheumatol Suppl</i>. 2005;73:19-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15693112/pubmed" id="15693112" target="_blank">15693112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536028">
<a name="29536028"></a>Parajuli S, Mandelbrot DA, Muth B, et al. Rituximab and monitoring strategies for late antibody-mediated rejection after kidney transplantation. <i>Transplant Direct</i>. 2017;3(12):e227. doi:10.1097/TXD.0000000000000746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/29536028/pubmed" id="29536028" target="_blank">29536028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19036077">
<a name="19036077"></a>Parodi E, Rivetti E, Amendola G, et al, “Long-Term Follow-Up Analysis After Rituximab Therapy in Children With Refractory Symptomatic ITP: Identification of Factors Predictive of a Sustained Response,” <i>Br J Haematol</i>, 2009, 144(4):552-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19036077/pubmed" id="19036077" target="_blank">19036077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22566601">
<a name="22566601"></a>Patel VL, Mahevas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. <i>Blood.</i> 2012;119(25):5989-5995. doi:10.1182/blood-2011-11-393975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22566601/pubmed" id="22566601" target="_blank">22566601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22681986">
<a name="22681986"></a>Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. <i>Am J Transplant</i>. 2012;12(9):2526-2531. doi:10.1111/j.1600-6143.2012.04126.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22681986/pubmed" id="22681986" target="_blank">22681986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24626432">
<a name="24626432"></a>Pendergraft WF 3rd, Cortazar FB, Wenger J, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. <i>Clin J Am Soc Nephrol</i>. 2014;9(4):736-744. doi:10.2215/CJN.07340713<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24626432/pubmed" id="24626432" target="_blank">24626432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21799148">
<a name="21799148"></a>Pereira T, Abitbol CL, Seeherunvong W, et al. Three decades of progress in treating childhood-onset lupus nephritis. <i>Clin J Am Soc Nephrol</i>. 2011;6(9):2192-2199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21799148/pubmed" id="21799148" target="_blank">21799148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33521513">
<a name="33521513"></a>Perrotta K, Kiernan E, Bandoli G, Manaster R, Chambers C. Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series. <i>Rheumatol Adv Pract</i>. 2021;5(1):rkaa074. doi:10.1093/rap/rkaa074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33521513/pubmed" id="33521513" target="_blank">33521513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21940214">
<a name="21940214"></a>Pfreundschuh M, Kuhnt E, Trümper L, et al, “CHOP-like Chemotherapy With or Without Rituximab in Young Patients With Good-Prognosis Diffuse Large-B-Cell Lymphoma: 6-Year Results of an Open-Label Randomised Study of the MabThera International Trial (MInT) Group,” <i>Lancet Oncol</i>, 2011, 12(11):1013-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21940214/pubmed" id="21940214" target="_blank">21940214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12072308">
<a name="12072308"></a>Pham PT, Wilkinson AH, Gritsch HA, et al. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease. <i>Transplant Proc</i>. 2002;34(4):1178-1181. doi:10.1016/s0041-1345(02)02754-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/12072308/pubmed" id="12072308" target="_blank">12072308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18039744">
<a name="18039744"></a>Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. <i>Arch Dis Child</i>. 2008;93(5):401-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/18039744/pubmed" id="18039744" target="_blank">18039744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31868632">
<a name="31868632"></a>Poeschel V, Held G, Ziepert M, et al; FLYER Trial Investigators; German Lymphoma Alliance. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet</i>. 2019;394(10216):2271-2281. doi:10.1016/S0140-6736(19)33008-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31868632/pubmed" id="31868632" target="_blank">31868632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31770441">
<a name="31770441"></a>Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Adv.</i> 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31770441/pubmed" id="31770441" target="_blank">31770441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19846889">
<a name="19846889"></a>Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood</i>. 2010;115(2):168-186. doi:10.1182/blood-2009-06-225565<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19846889/pubmed" id="19846889" target="_blank">19846889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20033225">
<a name="20033225"></a>Prytula A, Iijima K, Kamei K, et al. Rituximab in Refractory Nephrotic Syndrome. <i>Pediatr Nephrol</i>. 2010;25(3):461-468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20033225/pubmed" id="20033225" target="_blank">20033225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23432476">
<a name="23432476"></a>Puisset F, White-Koning M, Kamar N, et al. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. <i>Br J Clin Pharmacol</i>. 2013;76(5):734-740. doi:10.1111/bcp.12098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23432476/pubmed" id="23432476" target="_blank">23432476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17570702">
<a name="17570702"></a>Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. <i>Pediatr Blood Cancer</i>. 2008;50(4):822-825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17570702/pubmed" id="17570702" target="_blank">17570702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21821712">
<a name="21821712"></a>Ravandi F, O'Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. <i>Blood</i>. 2011;118(14):3818-3823. doi:10.1182/blood-2011-04-351502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21821712/pubmed" id="21821712" target="_blank">21821712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25497766">
<a name="25497766"></a>Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. <i>Autoimmun Rev</i>. 2015;14(4):304-313. doi:10.1016/j.autrev.2014.11.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/25497766/pubmed" id="25497766" target="_blank">25497766</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Riabni (rituximab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; June 2022.</div>
</li>
<li>
<div class="reference">
                  Riabni (rituximab) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; March 2021.</div>
</li>
<li>
<div class="reference">
                  Rituxan (rituximab) [prescribing information]. South San Francisco, CA: Genentech Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rituxan.2">
<a name="Rituxan.2"></a>Rituxan (rituximab) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Ltd; June 2023.</div>
</li>
<li>
<div class="reference">
                  Riximyo (rituximab) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24428673">
<a name="24428673"></a>Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10 002. <i>Br J Haematol</i>. 2014;165(1):102-111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24428673/pubmed" id="24428673" target="_blank">24428673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35879056">
<a name="35879056"></a>Rød BE, Torkildsen Ø, Myhr KM, Bø L, Wergeland S. Safety of breast feeding during rituximab treatment in multiple sclerosis. <i>J Neurol Neurosurg Psychiatry</i>. 2022;94(1):38-41. doi:10.1136/jnnp-2022-329545<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/35879056/pubmed" id="35879056" target="_blank">35879056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25139610">
<a name="25139610"></a>Rodrigo C, Rajapakse S, Gooneratne L. Rituximab in the treatment of autoimmune haemolytic anaemia. <i>Br J Clin Pharmacol</i>. 2015;79(5):709-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/25139610/pubmed" id="25139610" target="_blank">25139610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24847759">
<a name="24847759"></a>Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. <i>Am J Hematol</i>. 2014;89(9):E150-E155. doi:10.1002/ajh.23767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24847759/pubmed" id="24847759" target="_blank">24847759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20463186">
<a name="20463186"></a>Rubbert-Roth A, Tak PP, Zerbini C, et al, "Efficacy and Safety of Various Repeat Treatment Dosing Regimens of Rituximab in Patients With Active Rheumatoid Arthritis: Results of a Phase III Randomized Study (MIRROR)," <i>Rheumatology (Oxford)</i>, 2010, 49(9):1683-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20463186/pubmed" id="20463186" target="_blank">20463186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23569323">
<a name="23569323"></a>Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). <i>J Clin Oncol</i>. 2013;31(25):3061-3068. doi:10.1200/JCO.2012.46.9957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23569323/pubmed" id="23569323" target="_blank">23569323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25804280">
<a name="25804280"></a>Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. <i>J Am Soc Nephrol</i>. 2015;26(10):2545-2558.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/25804280/pubmed" id="25804280" target="_blank">25804280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22822077">
<a name="22822077"></a>Ruggenenti P, Cravecic P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. <i>J Am Soc Nephrol</i>. 2012;23(8):1416-1425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22822077/pubmed" id="22822077" target="_blank">22822077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15908650">
<a name="15908650"></a>Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. <i>J Clin Oncol</i>. 2005;23(15):3383-3389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15908650/pubmed" id="15908650" target="_blank">15908650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23433739">
<a name="23433739"></a>Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. <i>Lancet</i>. 2013. 381(9873):1203-1210. doi:10.1016/S0140-6736(12)61763-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23433739/pubmed" id="23433739" target="_blank">23433739</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ruxience (rituximab) [prescribing information]. New York, NY: Pfizer Labs; October 2023.</div>
</li>
<li>
<div class="reference">
                  Ruxience (rituximab) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28983798">
<a name="28983798"></a>Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. <i>Adv Ther</i>. 2017;34(10):2232-2273. doi:10.1007/s12325-017-0612-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28983798/pubmed" id="28983798" target="_blank">28983798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21176949">
<a name="21176949"></a>Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. <i>Lancet</i>. 2011;377(9759):42-51. doi:10.1016/S0140-6736(10)62175-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21176949/pubmed" id="21176949" target="_blank">21176949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27760868">
<a name="27760868"></a>Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. <i>Neurology</i>. 2016;87(20):2074-2081. doi:10.1212/WNL.0000000000003331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27760868/pubmed" id="27760868" target="_blank">27760868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23823112">
<a name="23823112"></a>Samochatova EV, Maschan AA, Shelikhova LN, et al. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study. <i>J Pediatr Hematol Oncol</i>. 2014;36(5):395-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23823112/pubmed" id="23823112" target="_blank">23823112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32535844">
<a name="32535844"></a>Sato M, Yamada M, Nakajima M, Miyama Y, Kitayama H. The case of Kawasaki disease after rituximab infusion triggered by human anti-chimeric antibodies. <i>CEN Case Rep</i>. 2020;9(4):392-394. doi:10.1007/s13730-020-00492-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32535844/pubmed" id="32535844" target="_blank">32535844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25784681">
<a name="25784681"></a>Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. <i>Blood</i>. 2015;125(25):3860-3867. doi:10.1182/blood-2014-11-551580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/25784681/pubmed" id="25784681" target="_blank">25784681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16638371">
<a name="16638371"></a>Scheinfeld N. A review of rituximab in cutaneous medicine. <i>Dermatol Online J</i>. 2006;12(1):3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16638371/pubmed" id="16638371" target="_blank">16638371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17938252">
<a name="17938252"></a>Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). <i>Blood.</i> 2008;111(1):109-111. doi:10.1182/blood-2007-03-078725<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17938252/pubmed" id="17938252" target="_blank">17938252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17233847">
<a name="17233847"></a>Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. <i>Br J Haematol</i>. 2007;136(3):451-461. doi:10.1111/j.1365-2141.2006.06448.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17233847/pubmed" id="17233847" target="_blank">17233847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21636861">
<a name="21636861"></a>Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. <i>Blood</i>. 2011;118(7):1746-1753. doi:10.1182/blood-2011-03-341131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21636861/pubmed" id="21636861" target="_blank">21636861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17244675">
<a name="17244675"></a>Sehn LH, Donaldson J, Filewich A, et al, “Rapid Infusion Rituximab in Combination With Corticosteroid-Containing Chemotherapy or as Maintenance Therapy is Well Tolerated and Can Safely be Delivered in the Community Setting,” <i>Blood</i>, 2007, 109(10):4171-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17244675/pubmed" id="17244675" target="_blank">17244675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31693429">
<a name="31693429"></a>Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. <i>J Clin Oncol</i>. 2020;38(2):155-165. doi:10.1200/JCO.19.00172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31693429/pubmed" id="31693429" target="_blank">31693429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11930095">
<a name="11930095"></a>Serinet MO, Jacquenin E, Habes D, et al, “Anti-CD20 Monoclonal Antibody (Rituximab) Treatment for Epstein-Barr Virus-Associated, B-Cell Lymphoproliferative Disease in Pediatric Liver Transplant Recipients,” <i>J Pediatr Gastroenterol Nutr</i>, 2002, 34(4):389-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/11930095/pubmed" id="11930095" target="_blank">11930095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34760113">
<a name="34760113"></a>Seyed Ahadi M, Sahraian MA, Shaygannejad V, et al. Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: a case-series study. <i>Caspian J Intern Med</i>. 2021;12(suppl 2):S491-S494. doi:10.22088/cjim.12.0.491<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/34760113/pubmed" id="34760113" target="_blank">34760113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29562156">
<a name="29562156"></a>Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. <i>N Engl J Med</i>. 2018;378(12):1107-1120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/29562156/pubmed" id="29562156" target="_blank">29562156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16093832">
<a name="16093832"></a>Sfikakis PP, Boletis JN, Tsokos GC. Rituximab Anti-B-Cell Therapy in Systemic Lupus Erythematosus: Pointing to the Future. <i>Curr Opin Rheumatol</i>. 2005;17(5):550-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16093832/pubmed" id="16093832" target="_blank">16093832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17947720">
<a name="17947720"></a>Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. <i>J Clin Oncol</i>. 2007;25(30):4730-4735.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17947720/pubmed" id="17947720" target="_blank">17947720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27471722">
<a name="27471722"></a>Shah S, Geetha D. Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis. <i>Immunotargets Ther</i>. 2015;4:173-183. doi:10.2147/ITT.S55516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27471722/pubmed" id="27471722" target="_blank">27471722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31365801">
<a name="31365801"></a>Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. <i>N Engl J Med</i>. 2019;381(5):432-443. doi:10.1056/NEJMoa1817073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31365801/pubmed" id="31365801" target="_blank">31365801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30995176">
<a name="30995176"></a>Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. <i>J Clin Oncol</i>. 2019;37(16):1391-1402. doi:10.1200/JCO.18.01460<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30995176/pubmed" id="30995176" target="_blank">30995176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22616969">
<a name="22616969"></a>Shen T, Braude S. Obliterative bronchiolitis after rituximab administration: a new manifestation of rituximab-associated pulmonary toxicity. <i>Intern Med J</i>. 2012;42(5):597-599. doi:10.1111/j.1445-5994.2012.02778.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22616969/pubmed" id="22616969" target="_blank">22616969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23645657">
<a name="23645657"></a>Shoji J, Lew SQ. The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD). <i>BMJ Case Rep</i>. 2013;2013:bcr2013009637. doi:10.1136/bcr-2013-009637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23645657/pubmed" id="23645657" target="_blank">23645657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31271628">
<a name="31271628"></a>Simões M, Miranda M, Carda J, Carmo A, Martins P. Rituximab use for lymphoplasmacytic lymphoma during continuous renal replacement therapy. <i>Rev Bras Ter Intensiva</i>. 2019;31(2):258-261. doi:10.5935/0103-507X.20190040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31271628/pubmed" id="31271628" target="_blank">31271628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31358450">
<a name="31358450"></a>Sinangil A, Ucar ZA, Koc Y, et al. Outcome of desensitization therapy in immunologically high-risk kidney transplantation: single-center experience. <i>Transplant Proc</i>. 2019;51(7):2268-2273. doi:10.1016/j.transproceed.2019.04.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31358450/pubmed" id="31358450" target="_blank">31358450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22473917">
<a name="22473917"></a>Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(5):625-639.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22473917/pubmed" id="22473917" target="_blank">22473917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32358226">
<a name="32358226"></a>Smith JB, Hellwig K, Fink K, Lyell DJ, Piehl F, Langer-Gould A. Rituximab, MS, and pregnancy.<i> Neurol Neuroimmunol Neuroinflamm</i>. 2020;7(4):e734. doi:10.1212/NXI.0000000000000734<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32358226/pubmed" id="32358226" target="_blank">32358226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22729997">
<a name="22729997"></a>Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Rheum</i>. 2012;64(11):3760-3769. doi:10.1002/art.34583<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22729997/pubmed" id="22729997" target="_blank">22729997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22147444">
<a name="22147444"></a>Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. <i>Arthritis Rheum</i>. 2012;64(3):835-842. doi:10.1002/art.34322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22147444/pubmed" id="22147444" target="_blank">22147444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28243475">
<a name="28243475"></a>Stahl K, Duong M, Schwarz A, et al. Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome. <i>Case Rep Nephrol</i>. 2017;2017:1372859. doi:10.1155/2017/1372859<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28243475/pubmed" id="28243475" target="_blank">28243475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20647199">
<a name="20647199"></a>Stone JH, Merkel PA, Spiera R, et al. Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis. <i>N Engl J Med</i>. 2010;363(3):221-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20647199/pubmed" id="20647199" target="_blank">20647199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20937671">
<a name="20937671"></a>Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of Joint Damage and Improved Clinical Outcomes With Rituximab Plus Methotrexate in Early Active Rheumatoid Arthritis: The IMAGE Trial. <i>Ann Rheum Dis</i>. 2011;70(1):39-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20937671/pubmed" id="20937671" target="_blank">20937671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18411418">
<a name="18411418"></a>Tam CS, O’Brien S, Wierda W, et al. Long-Term Results of the Fludarabine, Cyclophosphamide, and Rituximab Regimen as Initial Therapy of Chronic Lymphocytic Leukemia. <i>Blood</i>. 2008;112(4):975-980.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/18411418/pubmed" id="18411418" target="_blank">18411418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16933264">
<a name="16933264"></a>Tamminga RY, Bruin MC. Rituximab treatment for symptomatic chronic ITP. <i>Pediatr Blood Cancer</i>. 2006;47(5)(suppl):714-716.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16933264/pubmed" id="16933264" target="_blank">16933264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28164324">
<a name="28164324"></a>Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. <i>Muscle Nerve.</i> 2017;56(2):185-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28164324/pubmed" id="28164324" target="_blank">28164324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21732338">
<a name="21732338"></a>Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. <i>Cancer</i>. 2012;118(2):434-443. doi:10.1002/cncr.26303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21732338/pubmed" id="21732338" target="_blank">21732338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31245051">
<a name="31245051"></a>Teixeira V, Mohammad AJ, Jones RB, Smith R, Jayne D. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. <i>RMD Open</i>. 2019;5(1):e000905. doi:10.1136/rmdopen-2019-000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31245051/pubmed" id="31245051" target="_blank">31245051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16502413">
<a name="16502413"></a>Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i>. 2006;106(7):1569-1580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16502413/pubmed" id="16502413" target="_blank">16502413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20660823">
<a name="20660823"></a>Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 2010;28(24):3880-3889. doi:10.1200/JCO.2009.26.9456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20660823/pubmed" id="20660823" target="_blank">20660823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20807092">
<a name="20807092"></a>Thompson PA, Tam CS, Thursky K, Seymour JF. Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. <i>Leuk Lymphoma</i>. 2010;51(9):1592-1595. doi:10.3109/10428194.2010.509456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20807092/pubmed" id="20807092" target="_blank">20807092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33979489">
<a name="33979489"></a>Tiacci E, De Carolis L, Simonetti E, et al. Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. <i>N Engl J Med.</i> 2021;384(19):1810-1823. doi:10.1056/NEJMoa2031298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33979489/pubmed" id="33979489" target="_blank">33979489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34904799">
<a name="34904799"></a>Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. <i>N Engl J Med</i>. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/34904799/pubmed" id="34904799" target="_blank">34904799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30649616">
<a name="30649616"></a>Topakian R, Zimprich F, Iglseder S, et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. <i>J Neurol</i>. 2019;266(3):699-706. doi:10.1007/s00415-019-09191-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30649616/pubmed" id="30649616" target="_blank">30649616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22173060">
<a name="22173060"></a>Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. <i>Lancet Oncol</i>. 2012;13(2):196-206. doi:10.1016/S1470-2045(11)70300-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22173060/pubmed" id="22173060" target="_blank">22173060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24272588">
<a name="24272588"></a>Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). <i>J Neurol</i>. 2014;261(1):1-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24272588/pubmed" id="24272588" target="_blank">24272588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15598950">
<a name="15598950"></a>Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenström's macroglobulinemia. <i>Ann Oncol</i>. 2005;16(1):132-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15598950/pubmed" id="15598950" target="_blank">15598950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21454214">
<a name="21454214"></a>Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. <i>Clin Lymphoma Myeloma Leuk</i>. 2011;11(1):133-135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/21454214/pubmed" id="21454214" target="_blank">21454214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19506160">
<a name="19506160"></a>Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. <i>J Clin Oncol</i>. 2009;27(23):3830-3835.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/19506160/pubmed" id="19506160" target="_blank">19506160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24859363">
<a name="24859363"></a>Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. <i>Blood</i>. 2014;124(4):503-510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24859363/pubmed" id="24859363" target="_blank">24859363</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Truxima (rituximab) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Truxima.2">
<a name="Truxima.2"></a>Truxima (rituximab-abbs) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16700034">
<a name="16700034"></a>Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. <i>Cancer</i>. 2006;107(1):125-135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16700034/pubmed" id="16700034" target="_blank">16700034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33642561">
<a name="33642561"></a>Tsuzuki Y, Shiomi R, Ashitani K, et al. Rituximab-induced ileocolitis in a patient with gastric MALToma: a case report and literature review. <i>Intern Med</i>. 2021;60(5):731-738. doi:10.2169/internalmedicine.5119-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33642561/pubmed" id="33642561" target="_blank">33642561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22547089">
<a name="22547089"></a>Tun NM, Villani GM. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. <i>J Thromb Thrombolysis</i>. 2012;34(3):347-359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22547089/pubmed" id="22547089" target="_blank">22547089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27988971">
<a name="27988971"></a>Vacha M, Chery G, Hulbert A, et al. Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: does it work? <i>Clin Transplant</i>. 2017;31(3). doi:10.1111/ctr.12886<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27988971/pubmed" id="27988971" target="_blank">27988971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28487395">
<a name="28487395"></a>van den Brand JAJG, Ruggenenti P, Chianca A, et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. <i>J Am Soc Nephrol</i>. 2017;28(9):2729-2737. doi:10.1681/ASN.2016091022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/28487395/pubmed" id="28487395" target="_blank">28487395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27409338">
<a name="27409338"></a>Van Horebeek I, Knops N, Van Dyck M, Levtchenko E, Mekahli D. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature. <i>Acta Clin Belg</i>. 2017;72(3):147-155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/27409338/pubmed" id="27409338" target="_blank">27409338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20439641">
<a name="20439641"></a>van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. <i>J Clin Oncol</i>. 2010;28(17):2853-2858. doi:10.1200/JCO.2009.26.5827<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20439641/pubmed" id="20439641" target="_blank">20439641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20110520">
<a name="20110520"></a>van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials [published correction appears in <i>J Rheumatol</i>. 2010;37(10):2198]. <i>J Rheumatol</i>. 2010;37(3):558-567. doi:10.3899/jrheum.090856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20110520/pubmed" id="20110520" target="_blank">20110520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37080658">
<a name="37080658"></a>Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/37080658/pubmed" id="37080658" target="_blank">37080658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32458517">
<a name="32458517"></a>Vesely NC, Thomas RM, Rudnick E, Longo MI. Scar sarcoidosis following rituximab therapy. <i>Dermatol Ther</i>. 2020;33(6):e13693. doi:10.1111/dth.13693<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32458517/pubmed" id="32458517" target="_blank">32458517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677395">
<a name="16677395"></a>Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. <i>Arthritis Res Ther</i>. 2006;8(3):R83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16677395/pubmed" id="16677395" target="_blank">16677395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24770617">
<a name="24770617"></a>Vo AA, Choi J, Cisneros K, et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. <i>Transplantation</i>. 2014;98(3):312-319. doi:10.1097/TP.0000000000000064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/24770617/pubmed" id="24770617" target="_blank">24770617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20110854">
<a name="20110854"></a>Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. <i>Transplantation</i>. 2010;89(9):1095-1102. doi:10.1097/TP.0b013e3181d21e7f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20110854/pubmed" id="20110854" target="_blank">20110854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17597477">
<a name="17597477"></a>Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. <i>Am J Hematol</i>. 2007;82(10):916-919. doi:10.1002/ajh.20910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17597477/pubmed" id="17597477" target="_blank">17597477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22859855">
<a name="22859855"></a>Waldman M, Austin HA 3rd. Treatment of Idiopathic Membranous Nephropathy. <i>J Am Soc Nephrol</i>. 2012;23(10):1617-1630.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22859855/pubmed" id="22859855" target="_blank">22859855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26205134">
<a name="26205134"></a>Wallace G, Myers KC, Davies SM, Teusink A, Jodele S. Rapid rituximab infusion is safe in paediatric and young adult patients with non-malignant indications. <i>Br J Haematol</i>. 2016;173(3):480-481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/26205134/pubmed" id="26205134" target="_blank">26205134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15689912">
<a name="15689912"></a>Wang J, Wiley JM, Luddy R, et al. Chronic Immune Thrombocytopenic Purpura in Children: Assessment of Rituximab Treatment. <i>J Pediatr</i>. 2005;146(2):217-221.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15689912/pubmed" id="15689912" target="_blank">15689912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17061997">
<a name="17061997"></a>Watson R, Kozlowski T, Nickeleit V, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. <i>Am J Transplant.</i> 2006;6(12):3022-3029. doi:10.1111/j.1600-6143.2006.01554.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/17061997/pubmed" id="17061997" target="_blank">17061997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22764193">
<a name="22764193"></a>Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. <i>Nephrol Dial Transplant</i>. 2013;28(1):106-111. doi:10.1093/ndt/gfs285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22764193/pubmed" id="22764193" target="_blank">22764193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29296757">
<a name="29296757"></a>Westwood JP, Thomas M, Alwan F, et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. <i>Blood Adv</i>. 2017;1(15):1159-1166. doi:10.1182/bloodadvances.2017008268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/29296757/pubmed" id="29296757" target="_blank">29296757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16737873">
<a name="16737873"></a>Willems M, Haddad E, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. <i>J Pediatr</i>. 2006;148(5):623-627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/16737873/pubmed" id="16737873" target="_blank">16737873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10498591">
<a name="10498591"></a>Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). <i>Blood</i>. 1999;94(7):2217-2224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/10498591/pubmed" id="10498591" target="_blank">10498591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23953920">
<a name="23953920"></a>Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation. <i>J Heart Lung Transplant</i>. 2013;32(10):1034-1040. doi:10.1016/j.healun.2013.07.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/23953920/pubmed" id="23953920" target="_blank">23953920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20685255">
<a name="20685255"></a>Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: second-line treatment of chronic graft-versus-host disease. <i>Biol Blood Marrow Transplant</i>. 2011;17(1):1-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20685255/pubmed" id="20685255" target="_blank">20685255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15221999">
<a name="15221999"></a>Wong ET, Tishler R, Barron L, et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. <i>Cancer</i>. 2004;101(1):139-145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/15221999/pubmed" id="15221999" target="_blank">15221999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25534446">
<a name="25534446"></a>Woodle ES, Shields AR, Ejaz NS, et al. Prospective iterative trial of proteasome inhibitor-based desensitization. <i>Am J Transplant</i>. 2015;15(1):101-118. doi:10.1111/ajt.13050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/25534446/pubmed" id="25534446" target="_blank">25534446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33285756">
<a name="33285756"></a>Wu X, Lv Z, Li W, Meng Z, Wan SP. Epidermolysis bullosa acquisita as an adverse effect from rituximab therapy: A case report. <i>Medicine (Baltimore)</i>. 2020;99(49):e23496. doi:10.1097/MD.0000000000023496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/33285756/pubmed" id="33285756" target="_blank">33285756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34094516">
<a name="34094516"></a>Xue C, Yang B, Xu J, et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. <i>Clin Kidney J</i>. 2020;14(4):1042-1054. doi:10.1093/ckj/sfaa191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/34094516/pubmed" id="34094516" target="_blank">34094516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31435872">
<a name="31435872"></a>Yamanashi K, Chen-Yoshikawa TF, Hamaji M, et al. Outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation. <i>Gen Thorac Cardiovasc Surg</i>. 2020;68(2):142-149. doi:10.1007/s11748-019-01189-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/31435872/pubmed" id="31435872" target="_blank">31435872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30539030">
<a name="30539030"></a>Yamout BI, El-Ayoubi NK, Nicolas J, El Kouzi Y, Khoury SJ, Zeineddine MM. Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study. <i>J Immunol Re</i>s. 2018;2018:9084759. doi:10.1155/2018/9084759<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/30539030/pubmed" id="30539030" target="_blank">30539030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10589082">
<a name="10589082"></a>Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. <i>Am J Hematol</i>. 1999;62(4):247-250. doi:10.1002/(sici)1096-8652(199912)62:4&lt;247::aid-ajh9&gt;3.0.co;2-t<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/10589082/pubmed" id="10589082" target="_blank">10589082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20546023">
<a name="20546023"></a>Zaja F, Vianelli N, Volpetti S, et al. Low-Dose Rituximab in Adult Patients With Primary Immune Thrombocytopenia. <i>Eur J Haematol</i>. 2010;85(4):329-334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/20546023/pubmed" id="20546023" target="_blank">20546023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12531800">
<a name="12531800"></a>Zecca M, Nobili B, Ramenghi U, et al. Rituximab in the Treatment of Refractory Autoimmune Hemolytic Anemia in Children. <i>Blood</i>. 2003;101(10):3857-3861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/12531800/pubmed" id="12531800" target="_blank">12531800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32533450">
<a name="32533450"></a>Zhu W, Zhang Y, Wang Z, Fu Y, Yan Y. Monoclonal antibody-based treatments for neuromyelitis optica spectrum disorders: from bench to bedside. <i>Neurosci Bull</i>. 2020;36(10):1213-1224. doi:10.1007/s12264-020-00525-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/32533450/pubmed" id="32533450" target="_blank">32533450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22711851">
<a name="22711851"></a>Zurawska U, Hicks LK, Woo G, et al. Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis. <i>J Clin Oncol</i>. 2012;30(26):3167-3173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/abstract-text/22711851/pubmed" id="22711851" target="_blank">22711851</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12971 Version 340.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
